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SUMMARY 
 
This is the 21st annual statistical report of the National Cancer Registry. The report summarises cancer incidence, mortality 
and survival in Ireland for the period 1994 to 2014. 
 
Cancer incidence 
 On average, 37,591 cancers and other non-invasive tumours were diagnosed annually during the period 2012-2014. 
 Excluding non-melanoma skin cancers (NMSC), 20,804 cases of invasive cancer were diagnosed annually (11,101 males, 
9,703 females), representing 68% of all registered invasive cases. 
 Excluding NMSC, the top five most common invasive cancers diagnosed in men were prostate (30%), colorectal (13%) and 
lung cancer (12%), lymphoma (5%) and melanoma of the skin (4%) (Summary Figure 1).  
 Excluding NMSC, the top five cancers in women were breast (30%), lung (11%) and colorectal cancer (10%), melanoma of 
the skin (5%) and uterine cancer (corpus uteri, 5%).  
 The lifetime risk (to age 75 years) of an invasive cancer diagnosis (excluding NMSC) was approximately 1 in 3 for men and 
1 in 4 for women. 
 
Summary Figure 1. Numbers, percentages and rank of the most commonly diagnosed invasive cancers 
(excluding NMSC): annual averages 2012-2014 
MALES FEMALES ALL 
   
low-incidence invasive cancers are not shown (c.10% of cases), therefore percentages do not sum to 100%  
† vulva, vagina, uterus (NOS) and placenta 
 
Cancer mortality 
 An annual average of 8,655 deaths from cancer (males 4,590, females 4,065) occurred during the period 2011-2013, 
accounting for 30% of all deaths in Ireland during that period.  
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 The top five causes of cancer death in men were lung (24%), colorectal (13%), prostate (12%), pancreatic (5%) and 
oesophageal cancer (5%).  
 The top five causes of cancer death in women were lung (18%), breast (17%), colorectal (10%), ovarian (7%) and 
pancreatic cancer (6%).  
 The lifetime risk (to age 75 year) of dying from cancer was approximately 1 in 8 for men and 1 in 10 for women.  
 
Cancer rates comparison: Ireland vs. EU-27 in 2012 
 The cancer incidence rate in Irish males (invasive cancers excluding NMSC) was 10% higher than the EU average 
(453/100,000), partly due to increased diagnosis of prostate cancer in Ireland (52% higher). This was balanced against a 
lower incidence rate of lung cancer in Irish males (17% lower).  
 The mortality rate estimate from cancer in males was slightly lower (9%) than the EU27 average partly due to a lower 
than average mortality rate from lung cancer (19% lower). 
 The incidence rate in females was 16% higher than the EU average reflecting higher incidence of lung (55% higher), 
ovarian (24% higher), breast (13% higher) and colorectal cancer (14% higher) among Irish females. 
 The mortality rate in females was 13% higher than the EU27 average. This was largely due to the higher death rates for 
lung (34% higher), breast (22% higher) and ovarian cancer (38% higher) in Irish females.  
 
Cancer incidence trends  
 As might be expected in a country where both the population and average age is increasing, the number of new cancer 
cases increased almost year on year during the period 1994-2014. However, numbers of new cases registered slowed 
markedly from 2011 in males and less markedly in females from 2009.  
 After accounting for population growth and age structure, this translated into a statistically significant 2.3% annual 
decline in the male cancer rate during 2011-2014, and a less marked (non-significant) 0.9% annual decline in the female 
rate during the same period, excluding non-melanoma skin cancers (Summary Table 1, Summary Figure 2). 
 The decline in the overall male cancer incidence rate during 2011-2014 appears to be largely due to declining or static 
rates in prostate, lung and colorectal cancers. There was a steady and significant fall in the male lung cancer rate during 
1994-2014 and a marked decline in the prostate cancer rate during 2011-2014. This was balanced against steady 
increases in lymphomas and melanoma of the skin. 
 The less marked recent decline in the overall female cancer rate since 2011 was heavily influenced by a significant decline 
in the breast cancer rate since 2008, following an earlier period of increase (strongly influenced by mammographic 
screening). This was balanced against steady increases in lung cancer, skin melanoma, uterine cancer and lymphoma 
 Lung cancer incidence rates in males declined steadily over 1994-2014, while the female rate increased significantly over 
the same period. Lung cancer rates track smoking prevalence from decades past. As in other developed countries, it is 
likely that the period of peak smoking prevalence in females occurred some years later than that in males, which would 
help explain the contrasting lung cancer trends. 
 Melanoma of the skin is largely preventable, but the rates in both sexes increased steadily and significantly during 1994-
2014, particularly in men; the mortality rate also increased significantly in both sexes. The rates of non-melanoma skin 
cancer also increased steadily in both sexes over the full period 1994-2014. 
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Summary Table 1.  Summary of incidence and mortality rate trends, by sex and cancer type.  
Trends shown are for 1994-2014 (incidence) or 1994-2013 (mortality) unless otherwise indicated and are for age-
standardised rates – see Summary Figure 2 and Figures 4-1 to 4-30 (main report) for trends in case numbers and deaths 
MALES 
 INCIDENCE  
TREND 
MORTALITY  
TREND 
all invasive excl. NMSC* ↓2011-2014 
-2.3% per year 
↓ 
-1.5% per year 
INCIDENCE INCREASE   
C01-14 mouth & pharynx ↑2001-2014 ↓ 
C22 liver ↑ ↑ 
C43 melanoma of skin ↑ ↑ 
C64 kidney ↑ ↓ 
C73 thyroid ↑ ↔ 
C81 Hodgkin lymphoma ↑ ↓ 
C82-85 non-Hodgkin lymphoma ↑ ↓ 
INCIDENCE DECREASE   
C33-34 lung ↓ ↓ 
C61 prostate ↓2011-2014 ↓2004-2013 
C67 bladder ↓ ↓ 
C91-95 leukaemia ↓2004-2014 ↔2010-2013 
INCIDENCE STATIC   
C18-21 colorectum ↔2009-2014 ↓ 
C91-95 leukaemia ↓2004-2014 ↔2010-2013 
C16 stomach ↔2003-2014 ↓ 
C15 oesophagus ↔ ↓ 
C25 pancreas ↔ ↓2008-2013 
C71-72 brain & CNS ↔ ↔ 
C90 multiple myeloma ↔ ↓ 
 
FEMALES 
 INCIDENCE 
 TREND 
MORTALITY  
TREND 
all invasive excl. NMSC* ↔2011-2014  
-0.9% per year 
↓ 
-1.1% per year 
INCIDENCE INCREASE   
C01-14 mouth & pharynx ↑ ↔ 
C22 liver ↑ ↔2006-2013 
C33-34 lung ↑ ↑ 
C43 melanoma of skin ↑ ↑ 
C54 uterine ↑ ↑ 
C64 kidney ↑ ↔ 
C73 thyroid ↑ ↔2009-2013 
C81 Hodgkin lymphoma ↑ ↔ 
C82-85 non-Hodgkin lymphoma ↑ ↔ 
INCIDENCE DECREASE   
C15 oesophagus ↓ ↓ 
C16 stomach ↓ ↓ 
C50 breast ↓2008-2014 ↓ 
C56 ovary ↓ ↓ 
C67 bladder ↓ ↔ 
INCIDENCE STATIC   
C18-21 colorectum ↔ ↓ 
C25 pancreas ↔ ↔ 
C53 cervix ↔2010-2014 ↔ 
C91-95 leukaemia ↔2010-2014 ↓ 
C71-72 brain & CNS ↔ ↓ 
C90 multiple myeloma ↔ ↓ 
 
* 
 
Summary Figure 2. Trend in incidence and mortality by sex: All invasive cancers, excluding NMSC 
 CASE COUNT & TREND AGE-STANDARDISED RATE & TREND, PER 100,000 
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*C00-43, C45-96, i.e. excluding non-melanoma skin cancer (NMSC).  
** ↑=significant increase, ↓=significant decrease, ↔=no change  
The top three most common cancers in each sex are shown in bold. 
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Cancer mortality 
 Overall cancer mortality rates decreased steadily and significantly over the period 1994-2013, by an average of 1.5% 
annually in males and 1.1% annually in females (Summary Table 1, Summary Figure 2). 
 However, reflecting a growing and aging population, the total numbers of cancer deaths continues to increase annually. 
 Mortality rates for some individual cancers (notably melanoma of skin, uterine cancer, female lung cancer and male liver 
cancer) also show ongoing or recent increases.  
 
Cancer prevalence 
 As the number cancer of cases continues to rise in line with the population as expected, and mortality continues to fall, 
the number of persons living with cancer (or having a previous cancer diagnosis) continues to increase. 
 139,526 (43%) of all cancer patients registered by the National Cancer Registry during 1994-2014 (excluding non-
melanoma skin cancer patients) were still alive at the end of 2014, or 3% of the total Irish population in 2014. 
 Of these, 6,520 (4.7%) had been diagnosed with more than one distinct cancer type in a different body site (as opposed to 
multiple primaries of the same site, recurrences or metastases). 
 The top six most common cancer diagnoses among survivors were: breast (previously diagnosed in 23% of survivors), 
prostate (22%) and colorectal cancer (12%), skin melanoma (7%) and non-Hodgkin lymphoma (4%) (Summary Figure 3).  
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Summary Figure 3.  Site-specific cancer prevalence: number of cancer survivors (diagnosed 1994-2014) on 
31st December 2014, males and females combined 
 
 
 
 
Cancer survival 
 Over four consecutive diagnosis periods, five-year net survival for all cancers pooled (excluding NMSC and discounting 
deaths from other causes) increased incrementally: 1994-1998 (44%), 1999-2003 (51%), 2004-2008 (57%) and 2009-2013 
(61%) (Summary Figure 4). 
 Males and females showed similar patterns of survival improvement over time, although lung cancer survival showed 
more marked improvements among females. Notable improvements were also seen for colorectal, breast and prostate 
cancers, though with some evidence of a slowing down in the rate of improvement for breast and prostate cancer. 
 Estimates of ten-year net survival are presented in this report for the first time, based on all available follow-up of 
patients during 2010-2014. Estimates averaged 58% for male cancer patients, 54% for female patients, and ranged from 
as high as 96% for testicular cancer to as low as 7.5% for pancreatic cancer (Summary Figure 5). 
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Summary Figure 4.  Age-standardised 5-year and 10-year net survival (with 95% confidence intervals) for all 
cancers excluding NMSC, by diagnosis period 
ALL CANCERS (BOTH SEXES) ALL CANCERS (MALE) ALL CANCERS (FEMALE) 
   
 
 
 
Summary Figure 5. 5-year and 10-year net survival (age-standardised) for invasive cancers in Ireland, 2010-2014 
 
 
 
 
  
44.2%
50.7%
56.9%
61.1%
61.1%
39.9%
46.6%
52.9%
56.6%
0% 20% 40% 60% 80% 100%
1994-1998
1999-2003
2004-2008
2009-2013
2010-2014
net survival
10-yr
5-yr
40.0%
48.8%
57.5%
61.3%
61.7%
36.0%
44.9%
54.1%
57.8%
0% 20% 40% 60% 80% 100%
1994-1998
1999-2003
2004-2008
2009-2013
2010-2014
net survival
10-yr
5-yr
37.8%
51.7%
55.5%
59.8%
59.5%
33.2%
47.2%
50.3%
0.0%
54.2%
0% 20% 40% 60% 80% 100%
1994-1998
1999-2003
2004-2008
2009-2013
2010-2014
net survival
10-yr
5-yr
7.5%
10.6%
15.1%
18.3%
19.9%
24.5%
28.9%
39.8%
49.5%
52.3%
55.2%
57.0%
61.0%
70.9%
75.1%
85.7%
88.7%
95.5%
9.7%
16.4%
17.9%
21.5%
25.2%
27.3%
34.4%
49.5%
60.3%
61.6%
62.3%
62.6%
67.2%
76.2%
82.9%
88.7%
92.1%
96.3%
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
(C25) Pancreas
(C22) Liver
(C33-34) Lung & trachea
(C15) Oesophagus
(C71) Brain (malignant)
(C16) Stomach
(C56,C57.0-C57.7) Ovary & related
(C01-06,09-13) Head & neck
(C64-66,68) Kidney & related
(C91-95) Leukaemia
(C53) Cervix uteri
(C18-21) Colon & rectum
(C82-85) Non-Hodgkin lymphoma
(C54) Corpus uteri
(C50) Breast (female)
(C43) Melanoma skin
(C61) Prostate
(C62) Testis
Net survival %
5-yr
10-yr
Page | 7  
 
1. INCIDENCE 2012-2014 
 
 An average of 37,591 cancers and other (non-invasive) tumours was registered per year during 2012-2014 inclusive, 
representing an age-standardised incidence rate of 755 female cases and 794 male cases per 100,000 per year (Table 1-1). 
 Approximately 18% of these were non-invasive tumours (in situ carcinomas, tumours of uncertain behaviour and benign 
brain and CNS tumours) and 26% were invasive non-melanoma skin cancers (NMSC, 9,868 cases per year). 
 Invasive cancers (incl. NMSC) averaged 30,672 per year during 2012-2014, or an age-standardised rate of 548 female and 
720 male cases per 100,000 per year. 
 For all invasive cancers excluding NMSC, the figures most often quoted in international comparisons, 20,804 cases were 
registered annually, representing 68% of all registered invasive cases and equivalent to an incidence rate of 385 cases per 
100,000 females and 483 cases per 100,000 males per year. This rate was 26% higher for men than for women. 
 The cumulative lifetime risk (to age 75 years) of an invasive cancer diagnosis was approximately 1 in 3 for men and 1 in 4 
for women. Further statistics on lifetime risk by individual cancer type are given in Appendix I. 
 
Table 1-1. Annual average incidence of most common cancers: 2012-2014 
 CASES RATE** 
per 100,000 
% RISK to 
age 75 yr  
% of all invasive cancers  
excl. NMSC # 
ICD10 cancer site* male female all male female male female male female all 
C00-96 all invasive cancers 16,618 14,054 30,672 720.0 547.6 44.1 35.2 - - - 
C00-43,C45-96 invasive excl.NMSC # 11,101 9,703 20,804 483.3 384.5 33.4 26.6 100.0% 100.0% 100.0% 
C00-D48 all registered tumours 18,330 19,261 37,591 793.9 754.5 47.3 44.6 - - - 
D00-48 all non-invasive tumours 1,712 5,207 6,919 73.9 206.9 5.7 14.5 - - - 
mouth & pharynx 297 118 414 13.2 4.8 1.2 0.4 2.7% 1.2% 2.0% 
oesophagus 251 137 387 10.9 4.9 0.9 0.4 2.3% 1.4% 1.9% 
stomach 361 204 565 15.5 7.5 1.2 0.6 3.3% 2.1% 2.7% 
colorectum 1,476 1,013 2,489 63.8 38.1 4.9 2.9 13.3% 10.4% 12.0% 
liver  191 73 264 8.2 2.7 0.7 0.2 1.7% 0.8% 1.3% 
pancreas 266 252 518 11.5 9.1 0.9 0.7 2.4% 2.6% 2.5% 
lung and trachea 1,303 1,078 2,381 56.2 41.2 4.4 3.4 11.7% 11.1% 11.4% 
melanoma of skin 467 501 968 20.2 20.0 1.5 1.6 4.2% 5.2% 4.7% 
NMSC 5,517 4,351 9,868 236.7 163.1 16.1 11.7 - - - 
breast 29 2,919 2,947 1.2 121.6 0.1 9.5 0.3% 30.1% 14.2% 
cervix  277 277  11.5  0.9 - 2.9% 1.3% 
corpus uteri  465 465  19.2  1.7 - 4.8% 2.2% 
ovary  384 384  15.4  1.2 - 4.0% 1.8% 
other gynaecological†  103 103  4.1  0.3 - 1.1% 0.5% 
prostate 3,364  3,364 148.4  13.3  30.3% - 16.2% 
testis 172  172 7.3  0.5  1.5% - 0.8% 
kidney 383 208 591 16.7 8.3 1.3 0.7 3.5% 2.1% 2.8% 
bladder 304 134 438 13.0 4.7 1.0 0.3 2.7% 1.4% 2.1% 
all brain and CNS 298 331 629 13.0 13.5 1.0 1.1 - - - 
brain & CNS: malignant 207 164 371 9.0 6.7 0.8 0.5 1.9% 1.7% 1.8% 
brain and CNS: benign 57 131 188 2.5 5.2 0.2 0.4 - - - 
brain and CNS: uncertain 34 36 70 1.5 1.5 0.1 0.1 - - - 
thyroid gland 75 206 281 3.3 8.6 0.3 0.7 0.7% 2.1% 1.4% 
lymphoma (total) 500 410 911 21.8 16.5 1.7 1.4 4.5% 4.2% 4.4% 
Hodgkin lymphoma 81 59 140 3.6 2.6 0.3 0.2 0.7% 0.6% 0.7% 
non-Hodgkin lymphoma 420 351 771 18.2 13.9 1.5 1.2 3.8% 3.6% 3.7% 
multiple myeloma  163 108 271 7.1 4.0 0.5 0.3 1.5% 1.1% 1.3% 
leukaemia  290 192 483 12.6 7.6 0.9 0.6 2.6% 2.0% 2.3% 
other invasive tumours (‡) 1,002 757 1,760  
 
 
 
9.0% 7.8% 8.5% 
           
* invasive cancer included all tumours classified as behaviour 3 in ICD-O-3 classification (including some neoplasms previously classified as 
uncertain behaviour, e.g. polycythaemia vera) [1] 
**rates are standardised to the 1976 European standard population (ESP) [2]– see Appendix I for rates standardised to the 2013 ESP 
† vulva, vagina, uterus (NOS) and placenta 
‡ see Appendix I for further site-specific statistics 
# excluding non-melanoma skin cancer (NMSC) 
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Figure 1-1.  
Numbers, percentages and rank of the most commonly diagnosed invasive cancers (excluding NMSC): annual 
averages 2012-2014 
MALES FEMALES ALL 
   
low-incidence invasive cancers are not shown (c.10% of cases), therefore percentages do not sum to 100%  
† vulva, vagina, uterus (NOS) and placenta 
 
 If NMSC was excluded, prostate and female breast cancer were the most commonly diagnosed invasive cancers overall, 
and each comprised almost one-third of all invasive cancers in men and women respectively during the period 2012-
2014 (Figure 1-1). 
 Colorectal cancer, lung cancer, lymphoma, and melanoma of skin were the 2nd, 3rd, 4th and 5th most common cancers in 
males, respectively. 
 Lung cancer, colorectal cancer, melanoma of skin, and uterine cancer (corpus uteri) were the 2nd, 3rd, 4th and 5th most 
common cancers in females respectively. Lung cancer moved up the ranks from 3rd place to 2nd place ahead of colorectal 
cancer since publication of the NCR annual report of 2014 [1].  
 There was little change observed in the relative frequency or ranks of the common cancer types from the last annual 
report (2015) [2]. 
 
A more detailed breakdown of incidence statistics by cancer site is given in Appendix I.   
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2. MORTALITY 2011-2013 
 
 Cancer continues to be the second most common cause of death in Ireland, after diseases of the circulatory system, and 
an annual average of 8,655 deaths from cancer or other neoplasms occurred during the period 2011-2013.  
 Cancer represented about 30% of all deaths in Ireland for the period 2011-2013 and an age-standardised mortality rate 
of 149 deaths per 100,000 females and 204 deaths per 100,000 males per year (Table 2-1).  
 All-cancer mortality rates were approximately 36% higher in men than in women.  
 The lifetime risk (to age 75 year) of dying from cancer was approximately 1 in 10 for women and 1 in 8 for men.  
 
Table 2-1. Annual average mortality attributed to cancer: 2011-2013 
 DEATHS RATE* 
per 100,000 
% RISK to 
age 75 yr 
% of all 
cancer deaths 
 male   female  all  male   female  male   female  male   female  all  
C00-96 all cancers   4,590     4,065   8,655  203.6 149.2 12.7 10.1 100.0% 100.0% 100.0% 
mouth & pharynx     117       48     165  5.3 1.8 0.4 0.1 2.5% 1.2% 1.9% 
oesophagus     240      129     369  10.7 4.5 0.8 0.3 5.2% 3.2% 4.3% 
stomach     193      119     313  8.6 4.2 0.6 0.3 4.2% 2.9% 3.6% 
colorectal     594      424   1,018  26.4 14.8 1.7 0.9 12.9% 10.4% 11.8% 
liver     157      111     268  6.9 3.9 0.5 0.2 3.4% 2.7% 3.1% 
pancreas     246      237     483  10.9 8.5 0.8 0.6 5.4% 5.8% 5.6% 
lung   1,079      749   1,827  47.7 28.2 3.5 2.1 23.5% 18.4% 21.1% 
melanoma of skin      89       70     159  4.0 2.6 0.3 0.2 1.9% 1.7% 1.8% 
breast      694     694   26.5  2.0 0.0% 17.1% 8.0% 
cervix       89      89   3.8  0.3 0.0% 2.2% 1.0% 
corpus uteri       82      82   3.0  0.2 0.0% 2.0% 0.9% 
ovary      272     272   10.6  0.8 0.0% 6.7% 3.1% 
prostate     527      527  23.4  1.0  11.5% 0.0% 6.1% 
kidney     144       70     214  6.4 2.6 0.5 0.2 3.1% 1.7% 2.5% 
bladder     141       72     213  6.2 2.2 0.3 0.1 3.1% 1.8% 2.5% 
brain & CNS     157      108     265  7.0 4.4 0.6 0.4 3.4% 2.7% 3.1% 
lymphoma     146      142     288  6.4 5.2 0.3 0.3 3.5% 3.8% 3.6% 
multiple myeloma      94       79     173  4.2 2.7 0.3 0.2 2.0% 1.9% 2.0% 
leukaemia     161      104     264  7.1 3.7 0.4 0.2 3.5% 2.6% 3.1% 
others cancers     505      466     972      10.7% 11.2% 11.0% 
WHO mortality database [3] 
*rates are standardised to the 1976 European standard population (ESP) [4] 
 
 Lung cancer was the leading cause of cancer death in both sexes, averaging 1,827 deaths per year or 18% of cancer 
deaths in women and 24% of cancer deaths in men during the period 2011-2013 (Table 2-1, Figure 2-1).  
 Colorectal cancer was the next most common cause of cancer death in both sexes, averaging 1,018 deaths per year or 
13% of cancer deaths in males and 10% of cancer deaths in females.  
 Deaths from lung, colorectal, breast and prostate cancers combined made up almost half (47%) of all deaths from 
cancer during this period. 
 Deaths from cancers of the pancreas, oesophagus and stomach in males ranked 4th, 5th and 6th respectively, and 
comprised 15% of all cancer deaths in males. Mortality rankings for these high-fatality cancers ranked were much higher 
than their incidence rankings (Figure 1-2). 
 Deaths from cancers of the ovary and pancreas ranked 4th and 5th respectively in females and comprised almost 13% 
of cancer deaths in women, again much higher than the incidences ranking for these high-fatality cancers (Figure 1-2). 
A more detailed breakdown of mortality statistics by cancer site is given in Appendix II.  
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Figure 2-1. Number, percentages and rank of the most common cancer deaths: annual averages 2011-2013 
MALES  FEMALES ALL 
   
Cancers accounting for smaller percentages of cancer deaths (c10% in total) are not shown, therefore percentages do not sum to 100%. 
Data from WHO mortality database [3] 
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3. INCIDENCE AND MORTALITY: COMPARISON OF IRELAND AND EU-27 IN 2012 
 
The European Cancer Observatory (ECO) was developed in collaboration between IARC and 130 ENCR member registries [5]. 
The ECO provides a comprehensive window on cancer incidence, mortality and prevalence for Europe as a whole and for 
individual countries and registries. Estimates of cancer incidence and mortality in Ireland and EU-27 are presented for 2012, 
as this was the most recent comprehensive comparison available (Tables 3-1, 3-2). The average pooled estimates for 27 
members of the EU (in 2012) are presented for comparison. 
It cannot be excluded that some of this international variation might reflect differences in completeness of cancer 
registration. Almost half of the population of Europe falls outside the coverage of cancer registration and some countries 
may not have recorded all incident cancer cases that occurred within their borders, or incidence may have been estimated 
from mortality statistics. Some countries have regional registries that do not cover the whole population of the country (e.g. 
Spain, Italy, Poland, France and Germany) [10]. Ireland has a national cancer registry which covers the whole population 
(since 1994) and completeness of registration is estimated as 98% [11]. 
 
Table 3-1. Comparison of estimated incidence and mortality rates in Ireland with EU(27) average rates in 2012 
Invasive tumours, excluding NMSC: Males  
INCIDENCE MORTALITY 
 EU-27  
rate* 
Ireland  
rate* 
difference % 
prostate 110.8 168.7 52% 
oesophagus 8.4 12.5 49% 
leukaemia 11.8 17.0 44% 
melanoma 13.2 17.7 34% 
m. myeloma 5.5 7.0 27% 
testis 7.2 9.1 26% 
non-Hodgkin 13.8 17.2 25% 
Hodgkin 2.6 2.9 12% 
brain 8.1 9.0 11% 
colorectal 59.0 65.1 10% 
ALL SITES 452.9 499.6 10% 
pancreas 12.2 11.3 -7% 
kidney 17.4 15.7 -10% 
stomach 15.2 13.4 -12% 
lung 66.3 54.9 -17% 
bladder 29.1 20.5 -30% 
mouth & pharynx 18.3 11.9 -35% 
thyroid 3.5 1.9 -46% 
 
 EU-27  
rate* 
Ireland  
rate* 
difference % 
oesophagus 7.0 10.6 51% 
melanoma 2.8 3.8 36% 
m. myeloma 3.0 3.9 30% 
non-Hodgkin 4.9 5.8 18% 
prostate 18.9 22.1 17% 
brain 6.0 6.9 15% 
colorectal 23.8 25.4 7% 
leukaemia 6.8 7.1 4% 
Hodgkin 0.5 0.5 0% 
thyroid 0.4 0.4 0% 
kidney 6.7 6.5 -3% 
pancreas 11.9 11.0 -8% 
ALL SITES 211.9 193.1 -9% 
stomach 10.4 8.8 -15% 
lung 56.4 45.9 -19% 
testis 0.3 0.2 -33% 
bladder 8.4 5.6 -33% 
mouth & pharynx 7.2 4.3 -40% 
 
European Cancer Observatory [6][7]; *age-standardised rate (weighted by ESP 1976) 
 
 The age-standardised incidence rate in Irish males was 500/100,000, which was 10% higher than the EU average 
(453/100,000), partly due to higher incidence (or diagnosis levels) of prostate cancer in Ireland (52% higher). This was 
balanced against a lower incidence rate of lung cancer in Ireland (17% lower) (Table 3-1) 
 The mortality rate estimate from cancer in males was 193/100,000, which was slightly lower (9%) than the EU27 
average (212/100,000), partly due to a lower than average mortality rate from lung cancer (19% lower) (Table 3-1) 
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Table 3-2. Comparison of estimated incidence and mortality rates in Ireland with EU(27) average rates in 2012 
Invasive tumours, excluding NMSC: Females 
INCIDENCE MORTALITY 
 EU-27 
rate* 
Ireland 
rate* 
difference 
% 
oesophagus 2.0 5.1 155% 
lung 26.1 40.4 55% 
melanoma 13.1 18.6 42% 
non-Hodgkin 9.6 12.9 34% 
cervix 11.3 15.1 34% 
m. myeloma 5.5 7.0 27% 
ovary 12.6 15.6 24% 
bladder 6.1 7.5 23% 
Hodgkin 2.1 2.5 19% 
ALL SITES 330.1 382.4 16% 
leukaemia 7.1 8.2 15% 
colorectal 36.1 41.3 14% 
breast 108.8 122.4 13% 
kidney 8.0 8.7 9% 
pancreas 9.0 9.2 2% 
brain 5.9 5.9 0% 
stomach 7.1 6.7 -6% 
mouth & pharynx 5.5 4.9 -11% 
corpus uteri 17.9 15.6 -13% 
thyroid 9.3 4.7 -49% 
 
 EU-27 
rate* 
Ireland 
rate* 
difference 
% 
oesophagus 1.7 4.2 147% 
ovary 7.4 10.2 38% 
lung 20.6 27.6 34% 
m. myeloma 3.0 3.9 30% 
non-Hodgkin 3.0 3.8 27% 
breast 22.4 27.4 22% 
cervix 3.7 4.3 16% 
brain 4.0 4.6 15% 
ALL SITES 128.4 145.6 13% 
corpus uteri 3.3 3.7 12% 
melanoma 1.8 2.0 11% 
kidney 2.7 3.0 11% 
bladder 2.0 2.1 5% 
Hodgkin 0.3 0.3 0% 
colorectal 14.2 14.1 -1% 
pancreas 8.5 8.4 -1% 
leukaemia 4.0 3.8 -5% 
stomach 4.9 4.4 -10% 
mouth & pharynx 1.7 1.5 -12% 
thyroid 0.5 0.3 -40% 
 
European Cancer Observatory [6][7];  * age-standardised rate (weighted by ESP 1976) 
 
 The incidence rate in females was 382/100,000, 16% higher than the EU average (330/100,000), mostly reflecting higher 
incidence of lung (55% higher), melanoma (42% higher), cervix (34% higher), ovarian (24% higher), breast (13% higher) 
and colorectal cancer (14% higher) among Irish females (Table 3-2) 
 The mortality rate in females was 13% higher than the EU27 average: 146 vs. 128/100,000 respectively. This was largely 
due to the higher death rates for lung (34% higher), breast (22% higher) and ovarian cancer (38% higher) in Irish females 
relative to the European average (Table 3-2) 
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4. TRENDS IN INCIDENCE AND MORTALITY IN IRELAND 1994-2014 
 
Annual percentage changes (APC) in incidence over time were fitted by Joinpoint regression to case/death counts and annual 
age-standardised rates (ASR) of incidence and mortality [8][9].  
 In interpreting the trends reported in this section, possible changes in diagnostic activity (e.g. introduction or expansion 
of screening) or coding practices should be borne in mind, as well as possible changes in the true underlying risk of the 
cancers involved. Some mention of such factors is made under detailed results for specific cancer types (Figures 4-3 to 
4-30), along with brief summaries of confirmed or probable risk factors (main sources: World Cancer Research 
Foundation www.wcrf.org [10], American Cancer Society http://www.cancer.org/ [11]).  
 In some of the graphs presented (e.g. Figure 4-1) numbers of cases and deaths tend to increase over time due to natural 
population increase and aging but the age-standardised rate (ASR, calculated by reference to the 1976 European 
Standard Population weights) can actually decrease over time after adjustment for changes in age structure and 
population. 
 
Table 4-1 Summary of incidence and mortality age-standardised rate trends for cancers in males 
SITE (& INCIDENCE RANK) INCIDENCE  MORTALITY 
 PERIOD APC 95%CI TREND  PERIOD APC 95%CI TREND 
all invasive excl. NMSC 2011-2014 -2.3 [-4.5,-0.1] ↓  1994-2013 -1.5 [-1.7,-1.3] ↓ 
all invasive excl. NMSC & prostate 2008-2014 -0.5 [-1.0,0.0] ↓      
          
INCIDENCE RATE INCREASE          
C81 Hodgkin lymphoma†(4th) 1994-2014 2.2 [1.4,3.0] ↑  1994-2013 -4.4 [-6.4,-2.4] ↓ 
C82-85 non-Hodgkin lymphoma †(4th) 1994-2014 1.7 [1.3,2.1] ↑  1994-2013 -1.3 [-2.2,-0.3] ↓ 
C43 melanoma of skin (5th) 1994-2014 5.0 [4.4,5.7] ↑  1994-2013 5.1 [3.6,6.6] ↑ 
C64 kidney (6th) 1994-2014 2.8 [2.3,3.4] ↑  1994-2013 0.9 [-0.1,2.0] ↔ 
C01-14 mouth & pharynx (9th) 2001-2014 2.8 [2.1,3.6] ↑  1994-2013 -1.8 [-2.7,-1.0] ↓ 
C22 liver (14th) 1994-2014 6.5 [5.6,7.4] ↑  1994-2013 9.2 [7.8,10.6] ↑ 
C73 thyroid (17th) 1994-2014 6.4 [4.6,8.2] ↑  1994-2013 -0.4 [-2.2,1.5] ↔ 
C44 NMSC 2001-2014 3.0 [2.7,3.4] ↑      
          
INCIDENCE RATE DECREASE          
C61 prostate (1st) 2011-2014 -3.9 [-7.8,0.2] ↔  2004-2013 -3.6 [-4.8,-2.5] ↓ 
C33-34 lung (3rd) 1994-2014 -0.8 [-1.0,-0.6] ↓  1994-2013 -1.8 [-2.1,-1.5] ↓ 
C67 bladder (8th) 1994-2014 -2.9 [-3.4,-2.5] ↓  1994-2013 -1.0 [-1.7,-0.2] ↓ 
C91-95 leukaemia (10th) 2004-2014 -3.0 [-4.5,-1.4] ↓  2010-2013 6.0 [-6.2,19.8] ↔ 
          
INCIDENCE RATE STATIC          
C18-21 colorectum (2nd) 2009-2014 -1.4 [-2.9,0.2] ↔  1994-2013 -1.7 [-2.1,-1.2] ↓ 
C16 stomach (7th) 2003-2014 -0.2 [-0.9,0.5] ↔  1994-2013 -3.4 [-4.0,-2.9] ↓ 
C25 pancreas (11th) 1994-2014 0.6 [0.0,1.2] ↔  2008-2013 -3.4 [-6.6,-0.1] ↓ 
C15 oesophagus (12th) 1994-2014 -0.3 [-0.9,0.3] ↔  1994-2013 -0.8 [-1.3,-0.2] ↓ 
C71-72 malignant brain & CNS (13th) 1994-2014 -0.2 [-0.7,0.3] ↔  1994-2013 -0.6 [-1.4,0.2] ↔ 
C90 multiple myeloma  (16th) 1994-2014 0.3 [-0.3,0.9] ↔  1994-2013 -1.4 [-2.0,-0.8] ↓ 
C91-95 leukaemia excl. CLL 1994-2014 -0.2 [-0.8,0.5] ↔  
    APC: average annual percentage change in rate over period and 95% confidence interval (95%CI) based on annual data points fitted with 
Joinpoint regression. Trend: ↑=significant increase, ↓=significant decrease, ↔=no change (static), at the 95% level. The top five most 
common invasive cancers in males are shown in bold type. Incidence data covered the period 1994 to 2014 (21 years). Mortality data 
(where available) covered the period 1994-2013 (20 years). Where more than one discrete trend was observed over the full 20-21 year 
period, only the most recent trend is shown. See Figures 4-1 to 4-31 for a full visual representation of each individual cancer trend. 
†Lymphomas were pooled for rank. 
 
 The incidence rate of all invasive cancer (excl. NMSC) in males declined by 2.3% annually during the period 2011-2014 
after a prolonged and steady increase before 2011, although this recent trend was barely within the bounds of 
statistical significance. It is too early to tell if this downward trend will be sustained in males (Fig. 4-1).  
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 If the most common cancer, prostate cancer, was excluded from the dataset, the downward trend was much reduced   
(-0.5% annually during 2008-2014). The overall recent downward trend in male cancer rates was largely influenced by 
the declining rate of prostate cancer during the period 2011-2014 and lung cancer during 1994-2014.  
 From a healthcare provision perspective, the actual number of male cancer cases increased almost year on year during 
1994-2014, but the increase slowed during 2011-2014 (Fig. 4-1) mostly due to the fall-off in prostate cancers (Fig. 4-18) 
and to a lesser extent lung cancers (Fig. 4-9).  
 
Table 4-2 Summary of incidence and mortality age-standardised rate trends for cancers in females 
SITE (& INCIDENCE RANK) INCIDENCE     MORTALITY    
 PERIOD APC 95%CI TREND  PERIOD APC 95%CI TREND 
all invasive excl. NMSC 2011-2014 -0.9 [-3.4,1.7] ↔  1994-2013 -1.1 [-1.3,-0.9] ↓ 
all invasive excl. NMSC & breast 1994-2014 0.7 [0.6,0.9] ↑      
 
    
     
INCIDENCE RATE INCREASE          
C33-34 lung (2nd ) 1994-2014 2.3 [2.0,2.5] ↑  1994-2013 0.4 [0.0,0.7] ↑ 
C43 melanoma of skin (4th) 1994-2014 2.5 [2.0,3.1] ↑  1994-2013 2.2 [0.6,3.7] ↑ 
C54 uterine (5th ) 1994-2014 2.5 [2.0,3.0] ↑  1994-2013 1.6 [0.5,2.8] ↑ 
C81 Hodgkin lymphoma† (6th) 1994-2014 2.3 [1.0,3.6] ↑  1994-2013 -1.1 [-3.6,1.4] ↔ 
C82-85 non-Hodgkin lymphoma† (6th) 1994-2014 1.7 [1.1,2.3] ↑  1994-2013 -1.0 [-2.1,0.1] ↔ 
C64 kidney (10th ) 1994-2014 2.9 [2.2,3.5] ↑  1994-2013 0.6 [-0.7,1.9] ↔ 
C73 thyroid (11th ) 1994-2014 8.5 [7.2,9.8] ↑  2009-2013 12.4 [-2.3,29.5] ↔ 
C01-14 mouth & pharynx (17th) 1994-2014 2.1 [1.2,3.1] ↑  1994-2013 -0.7 [-1.9,0.5] ↔ 
C22 liver (20th) 1994-2014 5.0 [3.4,6.5] ↑  2006-2013 2.3 [-2.0,6.7] ↔ 
C44 NMSC  2000-2014 2.5 [2.1,2.9] ↑      
          
INCIDENCE RATE DECREASE          
C50 breast (1st) 2008-2014 -1.1 [-2.0,-0.2] ↓  1994-2013 -1.9 [-2.3,-1.5] ↓ 
C56 ovary (7th) 1994-2014 -0.6 [-1.1,-0.1] ↓  1994-2013 -0.8 [-1.5,-0.2] ↓ 
C16 stomach (12th) 1994-2014 -1.2 [-1.7,-0.7] ↓  1994-2013 -3.4 [-4.0,-2.8] ↓ 
C15 oesophagus (15th) 1994-2014 -1.1 [-1.6,-0.5] ↓  1994-2013 -1.5 [-2.3,-0.8] ↓ 
C67 bladder (16th) 1994-2014 -2.4 [-3.3,-1.5] ↓  1994-2013 -0.6 [-1.8,0.6] ↔ 
D06 cervix (in situ) 2011-2014 -8.9 [-16.1,-1.1] ↓      
          
INCIDENCE RATE STATIC          
C18-21 colorectum  (3rd) 1994-2014 0.0 [-0.3,0.3] ↔  1994-2013 -1.9 [-2.4,-1.5] ↓ 
C53 cervix (8th) 2010-2014 -6.7 [-14.4,1.7] ↔  1994-2013 -0.7 [-1.6,0.1] ↔ 
C25 pancreas (9th) 1994-2014 0.5 [-0.2,1.1] ↔  1994-2013 0.3 [-0.2,0.9] ↔ 
C91-95 leukaemia (13th) 2010-2014 -6.7 [-14.4,1.8] ↔  1994-2013 -1.4 [-2.5,-0.3] ↓ 
C71-72 brain & CNS (14th) 1994-2014 0.5 [-0.2,1.2] ↔  1994-2013 -1.2 [-2.1,-0.3] ↓ 
C90 multiple myeloma (18th) 1994-2014 0.0 [-1.0,1.0] ↔  1994-2013 -1.6 [-2.6,-0.5] ↓ 
C91-95 leukaemia excl. CLL 1994-2014 0.1 [-0.9,1.0] ↔      
D05 breast (in-situ) 2009-2014 -0.4 [-5.4,4.9] ↔      
APC: annual percentage change in rate over period and 95% confidence interval (95%CI) based on annual data points fitted with Joinpoint 
regression. Trend: ↑=significant increase, ↓=significant decrease, ↔=no change (static), at the 95% level.  
The top five most common cancers in females are shown in bold type. Incidence data covered the period 1994 to 2014 (21 years). Mortality 
data (where available) covered the period 1994-2013 (20 years). Where more than one discrete trend was observed over the full 20-21 
year period, only the most recent trend is shown. See Figures 4-1 to 4-31 for a full visual representation of each individual cancer trend. 
†Lymphomas were pooled for rank. 
 
 The incidence rate of all invasive cancer (excl. NMSC) in females declined by 0.9% annually during the period 2011-2014 
after a prolonged increase during 1994-2011. However, the recent trend was not statistically significant, and it is too 
early to tell if this will become a sustained downward trend (Fig. 4-1).  
 If breast cancer was excluded from the dataset, a steady and significant increase of 0.7% annually was the underlying 
trend in females; the recent decline in female breast cancer during 2008-2014 (1.1% annually) largely accounts for the 
overall marginal downward trend.  
 Cases of invasive cancer increased year on year during 1994-2014; however the accrual of new cases slowed 
significantly during 2009-2014, mostly attributable to fewer breast cancers (Fig. 4-1).  
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Figure 4-1. Trend in incidence and mortality by sex: C00-43, C45-96 All invasive cancers, excluding NMSC 
 
 CASE COUNT & TREND AGE-STANDARDISED RATE & TREND, PER 100,000 
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PERIOD APC 95%CI TREND 
MALE 1994-1998 1.7 [-0.1,3.6] ↔ 
 1998-2011 3.9 [3.6,4.2] ↑ 
 2011-2014 0.5 [-1.6,2.7] ↔ 
FEMALE 1994-2006 2.7 [2.3,3.0] ↑ 
 2006-2009 5.0 [-0.4,10.6] ↔ 
 2009-2014 1.6 [0.5,2.7] ↑ 
 
 
PERIOD APC 95%CI TREND 
MALE 1994-2011 1.3 [1.1,1.5] ↑ 
 
2011-2014 -2.3 [-4.5,-0.1] ↓ 
FEMALE 1994-2011 1.1 [0.9,1.3] ↑ 
 
2011-2014 -0.9 [-3.4,1.7] ↔ 
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PERIOD APC 95%CI TREND 
MALE 1994-2005 0.3 [-0.2,0.8] ↔ 
 
2005-2013 1.6 [0.8,2.4] ↑ 
FEMALE 1994-2013 1.0 [0.8,1.1] ↑ 
 
 
PERIOD APC 95%CI TREND 
MALE 1994-2013 -1.5 [-1.7,-1.3] ↓ 
FEMALE 1994-2013 -1.1 [-1.3,-0.9] ↓ 
 
female ○ male ● APC: annual percentage change over the PERIOD and 95% confidence interval (95%CI) based on data points fitted with 
Joinpoint regression.  Trend: ↑=significant increase, ↓=significant decrease, ↔=no change, at the 95% level. 
Incidence data covered the period 1994 to 2014. WHO mortality data (where available) covered the period 1994-2013. 
 
Males: 
 After a slow increase from 1994 to 1998, case numbers increased significantly up to 2011, thereafter the annual case 
count increased only marginally during 2011-2014. 
 After a sustained increase during 1994-2011, the incidence rate declined significantly during 2011-2014.  
 The decline in the overall rate of invasive cancers reflects a decline in prostate cancer rates since 2011 (following earlier 
increases), an ongoing fall in lung cancer rates and a marginal decline in colorectal cancer rates 2009-2014 (Table 4-1). 
 Numbers of deaths increased significantly over the period 2005-2013, following a more stable trend during 1994-2005. 
 After adjusting for population increase and aging, the mortality rate declined steadily during 1994-2013 (Fig. 4-1). 
Females: 
 Cases increased in a step-like fashion since 1994 with one brief period of rapid increase during 2006-2009. Thereafter, 
cases increased less steeply but significantly during 2009-2014.  
 Incidence rates increased steadily and significantly during 1994-2011 followed by a non-significant decline 2011-2014.  
 The recent marginal decline in the overall rate of invasive cancer in females was heavily influenced by a recent decline 
in breast cancer rates, against a background of decreases and increases in rates of other cancer types (Table 4-2). 
 Numbers of deaths increased steadily during 1994-2014, but the overall mortality rate declined over the same period 
after adjusting for population increase and aging.  
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Figure 4-2. Trend in incidence by sex: C00-43, C45-96 All invasive cancers, excluding NMSC, prostate cancer & 
breast cancer (in females) 
 
 CASE COUNT & TREND AGE-STANDARDISED RATE & TREND, PER 100,000 
IN
C
ID
EN
C
E 
  
 
 
PERIOD APC 95%CI TREND 
MALE 1994-1999 0.9 [0.1,1.8] ↑ 
 1999-2005 2.1 [1.3,2.9] ↑ 
 2005-2008 4.3 [0.9,7.9] ↑ 
 2008-2014 2.1 [1.6,2.7] ↑ 
FEMALE 1994-1998 0.9 [-1.1,3.0] ↔ 
 
1998-2014 2.8 [2.6,3.1] ↑ 
 
 
PERIOD APC 95%CI TREND 
MALE 1994-2005 -0.3 [-0.5,0.0] ↓ 
 2005-2008 1.3 [-1.6,4.4] ↔ 
 2008-2014 -0.5 [-1.0,0.0] ↓ 
FEMALE 1994-2014 0.7 [0.6,0.9] ↑ 
 
 
 
The graphs above are included to assess the influence of prostate cancer on trends in overall cancer rates in males and the 
influence of breast cancer on overall cancer trends in females (cf. Fig. 4-1). 
Males: 
 Case numbers increased significantly during 1994-2014, with one period of steeper increase during 2005-2008. 
 The incidence rate declined significantly during 1994-2005, with a marginal increase during 2005-2008. Thereafter, the 
rate declined significantly during 2008-2014, but with a less marked decline than that seen in for the dataset including 
prostate cancer. 
Females: 
 Case numbers increased marginally during 1994-1998, followed by a steeper and significant increase during 1998-2014.  
 The incidence rate increased steadily and significantly during 1994-2014.  
  
5,251
7,850
4,427
6,875
0
2000
4000
6000
8000
10000
12000
1
9
9
4
1
9
9
5
1
9
9
6
1
9
9
7
1
9
9
8
1
9
9
9
2
0
0
0
2
0
0
1
2
0
0
2
2
0
0
3
2
0
0
4
2
0
0
5
2
0
0
6
2
0
0
7
2
0
0
8
2
0
0
9
2
0
1
0
2
0
1
1
2
0
1
2
2
0
1
3
2
0
1
4
0
100
200
300
400
500
600
1
9
9
4
1
9
9
5
1
9
9
6
1
9
9
7
1
9
9
8
1
9
9
9
2
0
0
0
2
0
0
1
2
0
0
2
2
0
0
3
2
0
0
4
2
0
0
5
2
0
0
6
2
0
0
7
2
0
0
8
2
0
0
9
2
0
1
0
2
0
1
1
2
0
1
2
2
0
1
3
2
0
1
4
Page | 17  
 
Figure 4-3. Trend in incidence and mortality by sex: C01-14 Cancer of mouth & pharynx 
 
 CASE COUNT AND TREND AGE-STANDARDISED RATE & TREND, PER 100,000 
IN
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PERIOD APC 95%CI TREND 
MALE 1994-2001 -2.6 [-4.7,-0.5] ↓ 
 
2001-2014 5.5 [4.8,6.3] ↑ 
FEMALE 1994-1999 -2.0 [-11.0,7.9] ↔ 
 
1999-2014 4.9 [3.2,6.6] ↑ 
 
 
PERIOD APC 95%CI TREND 
MALE 1994-2001 -4.4 [-6.4,-2.2] ↓ 
 
2001-2014 2.8 [2.1,3.6] ↑ 
FEMALE 1994-2014 2.1 [1.2,3.1] ↑ 
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PERIOD APC 95%CI TREND 
MALE 1994-2010 -0.6 [-1.5,0.3] ↔ 
 
2010-2013 11.5 [0.4,23.9] ↑ 
FEMALE 1994-2013 1.2 [-0.1,2.4] ↔ 
 
 
PERIOD APC 95%CI TREND 
MALE 1994-2013 -1.8 [-2.7,-1.0] ↓ 
FEMALE 1994-2013 -0.7 [-1.9,0.5] ↔ 
 
 
 
Males: 
 After a period of significant decline from 1994, cases increased sharply and significantly during 2001-2014. 
 The incidence rate increased significantly during 2001-2014. 
 Deaths increased significantly during 2010-2013, following a stable trend (or marginal decline) during 1994-2010. 
 The mortality rate declined significantly during 1994-2013. 
Females:  
 After a period of decline from 1994, cases increased significantly during 1999-2014. 
 The incidence rate increased steadily over the full period 1994-2014. 
 Deaths increased marginally during 1994-2013. 
 The mortality rate was static or declined slightly over the same period. 
 
 The rather complex trends seen for these cancers may reflect trends in a number of established risk-factors, including 
tobacco smoking, alcohol consumption, and exposure to cancer-causing strains of human papillomavirus (HPV). 
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Figure 4-4. Trend in incidence and mortality by sex: C15 Oesophageal cancer 
 
 CASE COUNT AND TREND AGE-STANDARDISED RATE & TREND, PER 100,000 
IN
C
ID
EN
C
E 
  
 
 
PERIOD APC 95%CI TREND 
MALE 1994-2014 2.2 [1.6,2.7] ↑ 
FEMALE 1994-2014 0.8 [0.2,1.3] ↑ 
 
 
PERIOD APC 95%CI TREND 
MALE 1994-2014 -0.3 [-0.9,0.3] ↔ 
FEMALE 1994-2014 -1.1 [-1.6,-0.5] ↓ 
 
M
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PERIOD APC 95%CI TREND 
MALE 1994-2013 1.5 [1.0,2.1] ↑ 
FEMALE 1994-2013 0.4 [-0.3,1.0] ↔ 
 
 
PERIOD APC 95%CI TREND 
MALE 1994-2013 -0.8 [-1.3,-0.2] ↓ 
FEMALE 1994-2013 -1.5 [-2.3,-0.8] ↓ 
 
 
 
The number of incident cases was very similar to the number of deaths which reflects the poor prognosis for this cancer. 
Males: 
 Cases increased significantly during 1994-2014. 
 The incidence rate was static over the same period. 
 Deaths increased significantly during 1994-2013. 
 The mortality rate declined significantly during the same period.  
Females:  
 Cases increased significantly during 1994-2014, though not as markedly as in males  
 The incidence rate declined significantly over the same period. 
 Deaths were static during 1994-2013. 
 The mortality rate declined significantly over the same period. 
 
 Known risk factors for oesophageal cancer include smoking, being overweight or obese, and alcohol consumption, 
although their influence varies between the two main histological subtypes of oesophageal cancer (adenocarcinoma 
and squamous cell carcinoma). Although overall incidence rates are currently declining or stable, the balance between 
the influence of smoking and that of other factors may change over time and trends by histological subtype might be 
more informative. 
  
172
253
128
143
0
50
100
150
200
250
300
1
9
9
4
1
9
9
5
1
9
9
6
1
9
9
7
1
9
9
8
1
9
9
9
2
0
0
0
2
0
0
1
2
0
0
2
2
0
0
3
2
0
0
4
2
0
0
5
2
0
0
6
2
0
0
7
2
0
0
8
2
0
0
9
2
0
1
0
2
0
1
1
2
0
1
2
2
0
1
3
2
0
1
4
0
2
4
6
8
10
12
14
16
1
9
9
4
1
9
9
5
1
9
9
6
1
9
9
7
1
9
9
8
1
9
9
9
2
0
0
0
2
0
0
1
2
0
0
2
2
0
0
3
2
0
0
4
2
0
0
5
2
0
0
6
2
0
0
7
2
0
0
8
2
0
0
9
2
0
1
0
2
0
1
1
2
0
1
2
2
0
1
3
2
0
1
4
196
258
127
114
0
50
100
150
200
250
300
1
99
4
1
99
5
1
99
6
1
99
7
1
99
8
1
99
9
2
00
0
2
00
1
2
00
2
2
00
3
2
00
4
2
00
5
2
00
6
2
00
7
2
00
8
2
00
9
2
01
0
2
01
1
2
01
2
2
01
3
0
2
4
6
8
10
12
14
16
1
99
4
1
99
5
1
99
6
1
99
7
1
99
8
1
99
9
2
00
0
2
00
1
2
00
2
2
00
3
2
00
4
2
00
5
2
00
6
2
00
7
2
00
8
2
00
9
2
01
0
2
01
1
2
01
2
2
01
3
Page | 19  
 
Figure 4-5. Trend in incidence and mortality by sex: C16 Stomach cancer 
 
 CASE COUNT AND TREND AGE-STANDARDISED RATE & TREND, PER 100,000 
IN
C
ID
EN
C
E 
  
 
 
PERIOD APC 95%CI TREND 
MALE 1994-2002 -1.6 [-2.8,-0.3] ↓ 
 
2002-2014 2.6 [1.9,3.2] ↑ 
FEMALE 1994-2014 0.6 [0.1,1.1] ↑ 
 
 
PERIOD APC 95%CI TREND 
MALE 1994-2003 -2.8 [-3.8,-1.8] ↓ 
 
2003-2014 -0.2 [-0.9,0.5] ↔ 
FEMALE 1994-2014 -1.2 [-1.7,-0.7] ↓ 
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PERIOD APC 95%CI TREND 
MALE 1994-1999 -4.4 [-8.3,-0.3] ↓ 
 
1999-2013 -0.3 [-1.3,0.6] ↔ 
FEMALE 1994-2013 -1.6 [-2.2,-1.0] ↓ 
 
 
PERIOD APC 95%CI TREND 
MALE 1994-2013 -3.4 [-4.0,-2.9] ↓ 
FEMALE 1994-2013 -3.4 [-4.0,-2.8] ↓ 
 
 
 
Males: 
 After a period of decline during 1994-2002, cases increased sharply and significantly during 2002-2014.  
 The incidence rate declined significantly up to 2003, thereafter it was static during 2003-2014. 
 Deaths declined significantly during 1994-1999, and were stable or declined marginally thereafter up to 2013. 
 The mortality rate declined significantly during 1994-2013. 
Females:  
 Cases increased steadily during the full period 1994-2014. 
 The incidence rate decreased marginally over the same period. 
 Deaths declined significantly during 1994-2013. 
 The mortality rate declined significantly over the same period. 
 
 Exposure to the bacterium Helicobacter pylori (associated with disadvantaged social status in early childhood) and 
tobacco smoking are confirmed causes of stomach cancer, and there is probably an association with consumption of 
alcohol, salt-preserved foods and processed meats and with higher levels of body fat. Declines seen in incidence rates of 
stomach cancer here are consistent with declines in some of these factors, although the detailed trends (apparently 
slower decline in women and a stabilisation of rates in men) suggest potential for further improvement. 
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Figure 4-6. Trend in incidence and mortality by sex: C18-21 Colorectal cancer (including anus) 
 
 CASE COUNT AND TREND AGE-STANDARDISED RATE & TREND, PER 100,000 
IN
C
ID
EN
C
E 
  
 
 
PERIOD APC 95%CI TREND 
MALE 1994-2014 2.5 [2.2,2.7] ↑ 
FEMALE 1994-2014 1.9 [1.6,2.2] ↑ 
 
 
PERIOD APC 95%CI TREND 
MALE 1994-2009 0.3 [0.0,0.7] ↔ 
 
2009-2014 -1.4 [-2.9,0.2] ↔ 
FEMALE 1994-2014 0.0 [-0.3,0.3] ↔ 
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PERIOD APC 95%CI TREND 
MALE 1994-2013 0.7 [0.2,1.1] ↑ 
FEMALE 1994-2013 0.1 [-0.4,0.5] ↔ 
 
 
PERIOD APC 95%CI TREND 
MALE 1994-2013 -1.7 [-2.1,-1.2] ↓ 
FEMALE 1994-2013 -1.9 [-2.4,-1.5] ↓ 
 
 
 
Males: 
 Cases increased significantly and steadily during the full period 1994-2014. 
 After a long static period from 1994 to 2009, the incidence rate declined modestly but non-significantly during the 
period 2009-2014. 
 Deaths increased significantly during 1994-2013. 
 The mortality rate declined significantly during 1994-2013. 
Females:  
 Cases increased significantly during the full period 1994-2014. 
 The incidence rate was static over the same period. 
 Deaths were static during the full period 1994-2013. 
 The mortality rate declined significantly over the same period. 
 
 Modifiable factors that increase colorectal cancer risk include higher consumption of red meat, processed meat and 
alcohol and higher body fat, and low consumption of dietary fibre. Incidence rates of colorectal cancer in Ireland appear 
to be fairly static, with only limited evidence of a possible recent decrease. 
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Figure 4-7. Trend in incidence and mortality by sex: C22 Liver cancer (including intrahepatic bile ducts) 
 
 CASE COUNT AND TREND AGE-STANDARDISED RATE & TREND, PER 100,000 
IN
C
ID
EN
C
E 
  
 
 
PERIOD APC 95%CI TREND 
MALE 1994-2014 9.1 [8.2,10.1] ↑ 
FEMALE 1994-2014 7.1 [5.6,8.7] ↑ 
 
 
PERIOD APC 95%CI TREND 
MALE 1994-2014 6.5 [5.6,7.4] ↑ 
FEMALE 1994-2014 5.0 [3.4,6.5] ↑ 
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PERIOD APC 95%CI TREND 
MALE 1994-2013 12.0 [10.5,13.4] ↑ 
FEMALE 1994-2013 9.5 [7.9,11.1] ↑ 
 
 
PERIOD APC 95%CI TREND 
MALE 1994-2013 9.2 [7.8,10.6] ↑ 
FEMALE 1994-2006 10.7 [7.3,14.3] ↑ 
FEMALE 2006-2013 2.3 [-2.0,6.7] ↔ 
 
 
 
For males, the number of incident cases was very similar to the number of deaths during 1994-2014. For females, the 
number of recorded deaths generally exceeded the number of incident cases during 1999-2013. It is likely that some deaths 
attributed to primary liver cancer actually refer to secondary liver tumours (from a different primary site). 
Males: 
 Cases increased significantly during the full period 1994-2014 
 The incidence rate increased significantly over the same period. 
 Deaths increased significantly during 1994-2013. 
 The mortality rate increased significantly over the same period. 
Females:  
 Cases increased significantly during the full period 1994-2014. 
 The incidence rate increased significantly over the same period 
 Deaths increased significantly during the full period 1994-2013. 
 The mortality rate increased steeply and significantly over the period 1994-2006, thereafter the rate increased less 
steeply and non-significantly during 2006-2013. 
 
 Risk of liver cancer is increased by alcohol consumption, exposure to aflatoxins (fungal contamination in food) and being 
overweight or obese. Marked increases seen in primary liver cancer rates in Ireland suggest increases in the underlying 
risk factors among populations here, with alcohol consumption perhaps being the most important.  
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Figure 4-8. Trend in incidence and mortality by sex: C25 Pancreatic cancer 
 
 CASE COUNT AND TREND AGE-STANDARDISED RATE & TREND, PER 100,000 
IN
C
ID
EN
C
E 
  
 
 
PERIOD APC 95%CI TREND 
MALE 1994-2014 3.0 [2.4,3.7] ↑ 
FEMALE 1994-2014 2.3 [1.7,2.8] ↑ 
 
 
PERIOD APC 95%CI TREND 
MALE 1994-2014 0.6 [0.0,1.2] ↔ 
FEMALE 1994-2014 0.5 [-0.2,1.1] ↔ 
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PERIOD APC 95%CI TREND 
MALE 1994-2005 0.0 [-1.2,1.3] ↔ 
 2005-2008 9.8 [-7.5,30.3] ↔ 
 2008-2013 -0.1 [-3.7,3.6] ↔ 
FEMALE 1994-2013 2.2 [1.7,2.7] ↑ 
 
 
PERIOD APC 95%CI TREND 
MALE 1994-2005 -1.7 [-2.8,-0.6] ↓ 
 2005-2008 6.4 [-9.2,24.6] ↔ 
 2008-2013 -3.4 [-6.6,-0.1] ↓ 
FEMALE 1994-2013 0.3 [-0.2,0.9] ↔ 
 
 
 
The number of incident cases was very similar to the number of deaths throughout 1994-2014. 
Males: 
 Cases increased significantly during the full period 1994-2014. 
 The incidence rate increased modestly and non-significantly over the same period 
 Deaths increased non-significantly overall, with one steeper period of increase during 2005-2008. 
 The fitted mortality rate trend was complex but it was broadly static or showed a slight decline. 
Females:  
 Cases increased significantly during the full period 1994-2014. 
 The incidence rate increased non-significantly over the same period. 
 Deaths increased significantly during 1994-2013. 
 The mortality rate was static or increased marginally over the same period. 
 
 Tobacco use and higher levels of body fat are associated with higher risk of pancreatic cancer. Trends in Irish incidence 
rates, although not clear-cut, suggest that the underlying risk may be increasing.  
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Figure 4-9. Trend in incidence and mortality by sex: C33-34 Lung & tracheal cancer 
 
 CASE COUNT AND TREND AGE-STANDARDISED RATE & TREND, PER 100,000 
IN
C
ID
EN
C
E 
  
  PERIOD APC 95%CI TREND 
MALE 1994-1997 -1.4 [-4.5,1.8] ↔ 
 1997-2006 1.2 [0.5,1.9] ↑ 
 2006-2010 4.1 [1.0,7.2] ↑ 
 2010-2014 -0.1 [-1.9,1.7] ↔ 
FEMALE 1994-2014 4.1 [3.9,4.4] ↑ 
 
 
PERIOD APC 95%CI TREND 
MALE 1994-2014 -0.8 [-1.0,-0.6] ↓ 
FEMALE 1994-2014 2.3 [2.0,2.5] ↑ 
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PERIOD APC 95%CI TREND 
MALE 1994-1997 -4.6 [-9.8,1.0] ↔ 
 
1997-2013 0.9 [0.5,1.4] ↑ 
FEMALE 1994-2013 2.3 [1.9,2.6] ↑ 
 
 
PERIOD APC 95%CI TREND 
MALE 1994-2013 -1.8 [-2.1,-1.5] ↓ 
FEMALE 1994-2013 0.4 [0.0,0.7] ↑ 
 
 
Males: 
 Cases increased significantly during 1997-2006, followed by period of steeper increase during 2006-2010. Thereafter, 
the annual case count did not change during 2010 -2014 
 The incidence rate declined significantly during the full period 1994-2014 
 Deaths increased during 1997-2013, but the mortality rate declined steadily and significantly during the full period.  
Females:  
 Cases increased steadily and significantly during the full period 1994-2014 
 The incidence rate increased steadily and significantly over the same period 
 Deaths increased significantly during the full period 1994-2013, while the mortality rate increased significantly but less 
steeply over the same period. 
 
 The pattern of lung cancer incidence and mortality is markedly different in males and females. Incidence rates declined 
in males but increased steadily in females during 1994-2014. Mortality rates declined in males but increased in females 
over the same period. Lung cancer rates track smoking prevalence from decades earlier. It is likely that peak smoking 
prevalence in Irish females occurred somewhat later than in males, as seen in other countries [12–14], and that this 
accounts for the contrasting trends in male and female incidence rates for lung cancer. 
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Figure 4-10. Trend in incidence and mortality by sex: C43 Melanoma of skin 
 
 CASE COUNT AND TREND AGE-STANDARDISED RATE & TREND, PER 100,000 
IN
C
ID
EN
C
E 
  
 
 
PERIOD APC 95%CI TREND 
MALE 1994-2014 7.5 [6.8,8.1] ↑ 
FEMALE 1994-2014 4.7 [4.1,5.3] ↑ 
 
 
PERIOD APC 95%CI TREND 
MALE 1994-2014 5.0 [4.4,5.7] ↑ 
FEMALE 1994-2014 2.5 [2.0,3.1] ↑ 
 
M
O
R
TA
LI
TY
 
  
 
 
PERIOD APC 95%CI TREND 
MALE 1994-2013 7.6 [6.2,9.1] ↑ 
FEMALE 1994-2013 4.6 [3.1,6.1] ↑ 
 
 
PERIOD APC 95%CI TREND 
MALE 1994-2013 5.1 [3.6,6.6] ↑ 
FEMALE 1994-2013 2.2 [0.6,3.7] ↑ 
 
 
 
Males: 
 Cases increased steadily and significantly during the full period 1994-2014. 
 The incidence rate increased significantly over the same period. 
 Deaths increased significantly over the full period 1994-2013.  
 The mortality rate increased significantly over the same period. 
Females:  
 Cases increased steadily and significantly during the full period 1994-2014. 
 The incidence rate increased significantly over the same period. 
 Deaths increased significantly over the full period 1994-2013. 
 The mortality rate increased significantly over the same period. 
 
 While melanoma of the skin was more common in females overall, case counts and incidence rates for males steadily 
approached parity with females towards 2014. 
 Trends in mortality almost exactly mirrored those in incidence, for both sexes. 
 Over-exposure to ultraviolet radiation, particularly through episodic skin exposure involving severe sunburn, is the main 
risk factor for melanoma of the skin. Melanoma incidence is highest in more affluent populations within Ireland, and the 
marked increases in melanoma incidence rates in Ireland are probably associated with increases in holidaying outside 
Ireland.  
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Figure 4-11. Trend in incidence by sex: C44 Non-melanoma skin cancer 
 
 CASE COUNT AND TREND AGE-STANDARDISED RATE & TREND, PER 100,000 
IN
C
ID
EN
C
E 
  
 
 
PERIOD APC 95%CI TREND 
MALE 1994-2001 -0.3 [-1.4,0.7] ↔ 
 
2001-2014 6.0 [5.6,6.4] ↑ 
FEMALE 1994-2001 1.0 [-0.5,2.4] ↔ 
 
2001-2014 4.8 [4.3,5.3] ↑ 
 
 
PERIOD APC 95%CI TREND 
MALE 1994-2001 -1.7 [-2.8,-0.6] ↓ 
 
2001-2014 3.0 [2.7,3.4] ↑ 
FEMALE 1994-2000 -0.8 [-2.6,0.9] ↔ 
 
2000-2014 2.5 [2.1,2.9] ↑ 
 
 
 
Males: 
 After a static period up to 2001, cases increased significantly during 2001-2014. 
 The incidence rate increased significantly over the same period 
Females:  
 After a static period up to 2001, cases increased significantly during 2001-2014. 
 The incidence rate increased steadily and significantly during 2000-2014 after an earlier period of stability. 
 
 Though very common, non-melanoma skin cancer has relatively negligible effects on mortality. Mortality data were not 
available for this cancer on the WHO database. 
 Depending on subtype, non-melanoma skin cancers are associated with chronic (e.g. occupational) or episodic (e.g. 
holiday-related) overexposure to ultraviolet radiation. The more recent increases in incidence rates compared with 
melanoma may suggest that holiday-related exposure is now the main driving factor behind NMSC rates in Ireland, but 
further analysis by subtype may be informative (given that basal cell carcinomas of skin are less strongly associated than 
squamous cell carcinomas with chronic sun exposure).  
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Figure 4-12. Trend in incidence and mortality: C50 female breast cancer  
 
 CASE COUNT AND TREND AGE-STANDARDISED RATE & TREND, PER 100,000 
IN
C
ID
EN
C
E 
  
 PERIOD APC 95%CI TREND 
1994-2002 4.6 [3.8,5.4] ↑ 
2002-2005 0.7 [-5.3,7.2] ↔ 
2005-2008 7.9 [1.6,14.5] ↑ 
2008-2014 1.2 [0.3,2.1] ↑ 
 
PERIOD APC 95%CI TREND 
1994-2002 2.8 [2.0,3.6] ↑ 
2002-2005 -1.8 [-7.7,4.5] ↔ 
2005-2008 5.7 [-0.5,12.2] ↔ 
2008-2014 -1.1 [-2.0,-0.2] ↓ 
 
M
O
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TA
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TY
 
  
 PERIOD APC 95%CI TREND 
1994-2013 0.5 [0.1,0.8] ↑ 
 
PERIOD APC 95%CI TREND 
1994-2013 -1.9 [-2.3,-1.5] ↓ 
 
 
 
 Cases increased significantly during 1994-2002, followed by a slower annual increase during 2002-2005, another steeper 
increase during 2005 and 2008, then a more modest increase during 2008-2014. 
 The incidence rate trend shows a sustained increase during 1994-2002, followed by a period of stasis during 2002-2005, 
another marked though non-significant increase during 2005-2008 and a significant decrease over the period 2008-
2014. 
 The number of deaths increased slowly but significantly during 1994-2013, but the mortality rate declined significantly 
over the same period. 
 In large part, the detailed incidence trend for invasive breast cancer probably reflects the introduction of the national 
breast screening program (BreastCheck) in the eastern half of the country from 2000 and the rest of the country by 
2007. This is evident from the two peaks in incidence which followed the two roll-out phases. 
 The underlying risk of breast cancer risk is strongly though not exclusively linked to lifetime exposure to oestrogen and 
to factors that directly or indirectly influence this. Modifiable risk factors for breast cancer include alcohol consumption 
and (for post-menopausal breast cancer) body fatness. Trends in other risk factors, such as not bearing children or late 
first pregnancy (associated with societal changes) and early menarche and late menopause (associated in part with 
higher-energy diets), may also be influencing trends in breast cancer incidence rates in Ireland. 
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Figure 4-13. Trend in incidence: D05 carcinoma in situ of the breast (female) 
 
 CASE COUNT AND TREND AGE-STANDARDISED RATE & TREND, PER 100,000 
IN
C
ID
EN
C
E 
  
 PERIOD APC 95%CI TREND 
1994-2005 10.3 [6.8,13.9] ↑ 
2005-2009 19.5 [3.9,37.4] ↑ 
2009-2014 1.9 [-3.4,7.4] ↔ 
 
PERIOD APC 95%CI TREND 
1994-2006 8.5 [5.6,11.5] ↑ 
2006-2009 18.3 [-9.5,54.6] ↔ 
2009-2014 -0.4 [-5.4,4.9] ↔ 
 
 
 
 Cases increased significantly in a step-like manner overall, with a steeper annual increase during 2005-2009, followed by 
a more modest increase during 2009-2014. 
 The incidence rate increased significantly during 1994-2006, followed by a steeper increase during 2006-2009, then a 
period of stasis during 2009-2014. 
 As for invasive breast cancer, but to a greater extent, the incidence trend for carcinoma in situ of the breast probably 
largely reflects the introduction of the national breast screening program (BreastCheck) in the eastern half of the 
country from 2000 and the rest of the country by 2007. 
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Figure 4-14. Trend in incidence and mortality: C53 Cervical cancer 
 
 CASE COUNT AND TREND AGE-STANDARDISED RATE & TREND, PER 100,000 
IN
C
ID
EN
C
E 
  
 PERIOD APC 95%CI TREND 
1994-1999 -2.7 [-10.1,5.3] ↔ 
1999-2010 6.5 [4.0,9.1] ↑ 
2010-2014 -5.7 [-13.7,3.0] ↔ 
 
PERIOD APC 95%CI TREND 
1994-1999 -4.5 [-11.7,3.3] ↔ 
1999-2010 3.9 [1.5,6.4] ↑ 
2010-2014 -6.7 [-14.4,1.7] ↔ 
 
M
O
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TA
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TY
 
  
 PERIOD APC 95%CI TREND 
1994-2013 1.3 [0.4,2.2] ↑ 
 
PERIOD APC 95%CI TREND 
1994-2013 -0.7 [-1.6,0.1] ↔ 
 
 
 
 The case count declined modestly and non-significantly during 1994-1999, followed by a steep and significant increase 
during 1999-2010; thereafter, the case count declined non-significantly during 2010-2014. 
 The incidence rate declined non-significantly from 1994 to 1999, followed by a significant increase during 1999-2010, 
then a non-significant decline during 2010-2014. 
 Deaths increased significantly during 1994-2013, although numbers were small. 
 The mortality rate was static (or showed a marginal decline) during the full period of 1994-2013. 
 Exposure to cancer-causing strains of human papilloma virus (HPV) is the main (and probably necessary) risk factor for 
cervical cancer. 
 Screening activity (including the introduction of the organised Cervical Check program from 2008 onwards) may have 
had some bearing on the upward trend in rates seen during 1999-2010, and the increasing incidence rate during that 
period may (in part) reflect increased or earlier detection of invasive cases. Increased detection of in situ carcinomas of 
the cervix through screening (see next figure) should, in theory, lead to a reduction in incidence of invasive cases, but it 
may be too early to see this effect.  The apparent downward trends in case numbers and incidence rates from 2010 
onwards were not statistically significant, and the validity of these trends (or the interpretation of these trends if 
genuine) cannot readily be assessed at present.   
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Figure 4-15. Trend in incidence: D06 carcinoma in situ of cervix 
 
 CASE COUNT AND TREND AGE-STANDARDISED RATE & TREND, PER 100,000 
IN
C
ID
EN
C
E 
  
 PERIOD APC 95%CI TREND 
1994-2006 6.0 [4.4,7.6] ↑ 
2006-2011 16.5 [10.3,23.1] ↑ 
2011-2014 -11.2 [-18.1,-3.7] ↓ 
 
PERIOD APC 95%CI TREND 
1994-2006 2.9 [1.4,4.5] ↑ 
2006-2011 14.6 [8.4,21.1] ↑ 
2011-2014 -8.9 [-16.1,-1.1] ↓ 
 
 
 
 The case count increased significantly during 1994-2006, followed by a steeper and significant increase during 2006-
2011. Thereafter, the case count declined significantly during 2011-2014. 
 The incidence rate increased significantly up to 2006, followed by a significant and steeper increase during 2006-2011, 
then by a significant decline during 2011-2014. 
 The incidence rate of in situ cervical cancer increased in a two-step fashion during 1994-2011, the steeper period of 
increase (2006-2011) probably due to widespread introduction of screening through the CervicalCheck program (2008 
onwards). The reason for the marked decline in the incidence rate during 2011-2014 is unclear, although some 
reduction might be expected after several rounds of screening have picked up prevalent (but previously undiagnosed) 
cases. 
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Figure 4-16. Trend in incidence and mortality: C54 Uterine cancer 
 
 CASE COUNT AND TREND AGE-STANDARDISED RATE & TREND, PER 100,000 
IN
C
ID
EN
C
E 
  
 PERIOD APC 95%CI TREND 
1994-2014 4.8 [4.3,5.3] ↑ 
 
PERIOD APC 95%CI TREND 
1994-2014 2.5 [2.0,3.0] ↑ 
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O
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TY
 
  
 PERIOD APC 95%CI TREND 
1994-2013 3.8 [2.7,4.9] ↑ 
 
PERIOD APC 95%CI TREND 
1994-2013 1.6 [0.5,2.8] ↑ 
 
 
 
 The case count increased steeply and significantly during the full period 1994-2014. 
 The incidence rate increased significantly over the same period. 
 Deaths increased significantly during the full period 1994-2013. 
 The mortality rate increased significantly over the same period. 
 As in breast cancer, many of the risk factors for uterine cancer concern lifetime exposure to oestrogen. Before 
menopause, the ovaries are the major source of the two main female hormones, oestrogen and progesterone. A shift in 
the balance of these hormones towards more oestrogen increases a woman's risk for developing uterine cancer. Factors 
that affect this balance include use of hormone-replacement therapy (progesterone-unopposed HRT — increased risk), 
use of the combined contraceptive pill (reduced risk), increased body fatness and low levels of physical activity 
(increased risk).  
  
182
490
0
100
200
300
400
500
600
1
9
9
4
1
9
9
5
1
9
9
6
1
9
9
7
1
9
9
8
1
9
9
9
2
0
0
0
2
0
0
1
2
0
0
2
2
0
0
3
2
0
0
4
2
0
0
5
2
0
0
6
2
0
0
7
2
0
0
8
2
0
0
9
2
0
1
0
2
0
1
1
2
0
1
2
2
0
1
3
2
0
1
4
0
5
10
15
20
25
1
9
9
4
1
9
9
5
1
9
9
6
1
9
9
7
1
9
9
8
1
9
9
9
2
0
0
0
2
0
0
1
2
0
0
2
2
0
0
3
2
0
0
4
2
0
0
5
2
0
0
6
2
0
0
7
2
0
0
8
2
0
0
9
2
0
1
0
2
0
1
1
2
0
1
2
2
0
1
3
2
0
1
4
47
90
0
100
200
300
400
500
600
1
99
4
1
99
5
1
99
6
1
99
7
1
99
8
1
99
9
2
00
0
2
00
1
2
00
2
2
00
3
2
00
4
2
00
5
2
00
6
2
00
7
2
00
8
2
00
9
2
01
0
2
01
1
2
01
2
2
01
3
0
5
10
15
20
25
1
99
4
1
99
5
1
99
6
1
99
7
1
99
8
1
99
9
2
00
0
2
00
1
2
00
2
2
00
3
2
00
4
2
00
5
2
00
6
2
00
7
2
00
8
2
00
9
2
01
0
2
01
1
2
01
2
2
01
3
Page | 31  
 
Figure 4-17. Trend in incidence and mortality: C56 Ovarian cancer 
 
 CASE COUNT AND TREND AGE-STANDARDISED RATE & TREND, PER 100,000 
IN
C
ID
EN
C
E 
  
 PERIOD APC 95%CI TREND 
1994-2014 1.5 [1.1,2.0] ↑ 
 
PERIOD APC 95%CI TREND 
1994-2014 -0.6 [-1.1,-0.1] ↓ 
 
M
O
R
TA
LI
TY
 
  
 PERIOD APC 95%CI TREND 
1994-2013 1.4 [0.8,2.0] ↑ 
 
PERIOD APC 95%CI TREND 
1994-2013 -0.8 [-1.5,-0.2] ↓ 
 
 
 
 The case count increased significantly during the full period 1994-2014. 
 The incidence rate decreased modestly but significantly over the same period. 
 Deaths increased significantly during the full period 1994-2013. 
 The mortality rate declined significantly over the same period. 
 Risk factors for ovarian cancer include obesity (high BMI; increased risk), use of HRT (progesterone unopposed HRT; 
increased risk), use of the combined contraceptive pill (reduced risk), multiparity (> 1 pregnancy and/or first full term 
pregnancy before 26; reduced risk), family history of ovarian cancer. Adult attained height appears to be a convincing 
cause of ovarian cancer, probably as a marker for genetic, environmental, hormonal and nutritional factors affecting 
growth.  
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Figure 4-18. Trend in incidence and mortality: C61 Prostate cancer 
 
 CASE COUNT AND TREND AGE-STANDARDISED RATE & TREND, PER 100,000 
IN
C
ID
EN
C
E 
  
 PERIOD APC 95%CI TREND 
1994-2004 9.0 [7.9,10.2] ↑ 
2004-2011 5.2 [3.5,7.0] ↑ 
2011-2014 -1.4 [-5.7,3.1] ↔ 
 
PERIOD APC 95%CI TREND 
1994-2004 7.5 [6.4,8.6] ↑ 
2004-2011 2.2 [0.6,3.8] ↑ 
2011-2014 -3.9 [-7.8,0.2] ↔ 
 
M
O
R
TA
LI
TY
 
  
 PERIOD APC 95%CI TREND 
1994-2013 0.1 [-0.2,0.5] ↔ 
 
PERIOD APC 95%CI TREND 
1994-2004 -0.8 [-1.8,0.3] ↔ 
2004-2013 -3.6 [-4.8,-2.5] ↓ 
 
 
 
 The case count increased significantly and steeply during 1994-2004, followed by a lesser though significant increase 
during 2004-2011. Thereafter, the case count declined during 2011-2014. 
 The incidence rate increased significantly and steeply during 1994-2004, followed by a lesser though significant increase 
during 2004-2011. Thereafter, the rate declined significantly during 2011-2014. 
 The number of deaths was static during the full period 1994-2013. 
 The mortality rate declined marginally during 1994-2004, followed by a significant decline during 2004-2013. 
 Increasing incidence up to 2011 probably reflected large-scale PSA testing of asymptomatic men. The number of PSA 
tests carried out in Ireland increased five-fold between 1995 and 2004 [15]. 
 There is strong evidence that being overweight or obese increases the risk of being diagnosed with advanced prostate 
cancer, and that developmental factors in the womb, childhood and adolescence that influence growth are linked to an 
increased risk of prostate cancer. However, incidence trends for this cancer are so strongly influenced by PSA-testing 
that trends related to such underlying risk factors are difficult to establish.  
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Figure 4-19. Trend in incidence and mortality by sex: C64 Kidney cancer 
 
 CASE COUNT AND TREND AGE-STANDARDISED RATE & TREND, PER 100,000 
IN
C
ID
EN
C
E 
  
 
 
PERIOD APC 95%CI TREND 
MALE 1994-2014 5.4 [4.8,6.0] ↑ 
FEMALE 1994-2014 5.0 [4.4,5.6] ↑ 
 
 
PERIOD APC 95%CI TREND 
MALE 1994-2014 2.8 [2.3,3.4] ↑ 
FEMALE 1994-2014 2.9 [2.2,3.5] ↑ 
 
M
O
R
TA
LI
TY
 
  
 
 
PERIOD APC 95%CI TREND 
MALE 1994-2013 3.6 [2.6,4.7] ↑ 
FEMALE 1994-2013 2.6 [1.3,3.9] ↑ 
 
 PERIOD APC 95%CI TREND 
MALE 1994-2013 0.9 [-0.1,2.0] ↔ 
FEMALE 1994-2013 0.6 [-0.7,1.9] ↔ 
 
 
 
Males: 
 Cases increased significantly during the full period 1994-2014. 
 The incidence rate increased significantly over the same period. 
 Deaths increased significantly over the full period 1994-2013. 
 The mortality rate was static (or showed a marginal increase) over the same period.  
Females:  
 Cases increased steadily and significantly during the full period 1994-2014. 
 The incidence rate increased steadily and significantly over the same period.  
 Deaths increased significantly during the full period 1994-2013. 
 The mortality rate was static (or showed a marginal increase) over the same period.  
 
 There is strong evidence that smoking and being overweight or obese increase the risk of kidney cancer.  
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Figure 4-20. Trend in incidence and mortality by sex: C67 Bladder cancer 
 
 CASE COUNT AND TREND AGE-STANDARDISED RATE & TREND, PER 100,000 
IN
C
ID
EN
C
E 
  
 
 
 
PERIOD APC 95%CI TREND 
MALE 1994-2014 -0.6 [-0.9,-0.2] ↓ 
FEMALE 1994-2014 -0.2 [-1.0,0.7] ↔ 
 
PERIOD APC 95%CI TREND 
MALE 1994-2014 -2.9 [-3.4,-2.5] ↓ 
FEMALE 1994-2014 -2.4 [-3.3,-1.5] ↓ 
 
M
O
R
TA
LI
TY
 
  
 
 
PERIOD APC 95%CI TREND 
MALE 1994-2013 1.4 [0.6,2.2] ↑ 
FEMALE 1994-2013 1.5 [0.2,2.9] ↑ 
 
 PERIOD APC 95%CI TREND 
MALE 1994-2013 -1.0 [-1.7,-0.2] ↓ 
FEMALE 1994-2013 -0.6 [-1.8,0.6] ↔ 
 
 
 
Males: 
 Cases declined significantly during the full period 1994-2014. 
 The incidence rate declined significantly over the same period. 
 Deaths increased significantly over the full period 1994-2013. 
 The mortality rate declined significantly over the same period. 
Females:  
 Cases declined very modestly during the full period 1994-2014. 
 The incidence rate declined steadily and significantly over the same period.  
 Deaths increased significantly overall during the full period 1994-2013. 
 The mortality rate was static (or declined marginally) during the same period. 
 
 An important caution regarding interpretation of bladder cancer trends is that, for both sexes, the downward trend in 
incidence rates is probably exaggerated by changes in diagnosis or coding (in particular, a higher proportion of bladder 
tumours may have been coded as non-invasive in more recent years). Although total numbers of cases coded as 
invasive bladder cancer fell from 522 in 1994 to 473 in 2014, numbers of bladder tumours including in situ carcinomas 
and tumours of uncertain behaviour actually increased from 533 cases in 1994 to 818 in 2016.  
 True changes in the underlying risk of invasive bladder cancer, and the possible influence of smoking (the most 
important risk factor for bladder cancer) on the trends seen, are thus difficult to assess. 
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Figure 4-21. Trend in incidence and mortality by sex: C71-72 Brain & central nervous system cancer 
 
 CASE COUNT AND TREND AGE-STANDARDISED RATE & TREND, PER 100,000 
IN
C
ID
EN
C
E 
  
 
 
PERIOD APC 95%CI TREND 
MALE 1994-2014 2.0 [1.5,2.5] ↑ 
FEMALE 1994-2014 2.3 [1.6,3.1] ↑ 
 
 
PERIOD APC 95%CI TREND 
MALE 1994-2014 -0.2 [-0.7,0.3] ↔ 
FEMALE 1994-2014 0.5 [-0.2,1.2] ↔ 
 
M
O
R
TA
LI
TY
 
  
 
 
PERIOD APC 95%CI TREND 
MALE 1994-2013 1.6 [0.8,2.5] ↑ 
FEMALE 1994-2013 0.7 [-0.2,1.6] ↔ 
 
 
PERIOD APC 95%CI TREND 
MALE 1994-2013 -0.6 [-1.4,0.2] ↔ 
FEMALE 1994-2013 -1.2 [-2.1,-0.3] ↓ 
 
 
 
Males: 
 Cases of invasive brain / CNS cancer increased significantly during the full period 1994-2014. 
 The incidence rate was static over the same period. 
 Deaths increased significantly over the full period 1994-2013. 
 The mortality rate was static (or declined marginally) over the same period. 
Females:  
 Cases increased significantly during the full period 1994-2014. 
 The incidence rate was static over the same period. 
 Numbers of deaths were static or increased marginally during the full period 1994-2013. 
 The mortality rate declined significantly during the same period. 
 Most brain tumours are not linked with any known risk factors and have no obvious cause. The only environmental risk 
factor for brain tumours is radiation exposure, e.g. in people who received radiation to the brain as children as part of 
their treatment for leukaemia. Most people with brain tumours do not have a family history of the disease, but in rare 
cases brain and spinal cord cancers are associated with familial-linked conditions. 
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Figure 4-22. Trend in incidence by sex: D32-D33 Benign tumours of brain & central nervous system 
 
 CASE COUNT AND TREND AGE-STANDARDISED RATE & TREND, PER 100,000 
IN
C
ID
EN
C
E 
  
 
 
PERIOD APC 95%CI TREND 
MALE 1994-2014 3.0 [1.8,4.2] ↑ 
FEMALE 1994-2014 4.0 [3.1,4.9] ↑ 
 
 
PERIOD APC 95%CI TREND 
MALE 1994-2014 0.8 [-0.5,2.0] ↔ 
FEMALE 1994-2014 1.6 [0.7,2.5] ↑ 
 
 
 
Males: 
 Cases increased significantly during the full period 1994-2014. 
 The incidence rate increased marginally but non-significantly over the same period. 
Females:  
 Cases increased significantly during the full period 1994-2014. 
 The incidence rate increased significantly over the same period. 
 
 While invasive malignant brain & CNS tumours were more frequent in men (Fig 3-21), benign brain and CNS tumours 
(which can also be fatal) were more common in women (Fig 3-22). No mortality data for benign brain and CNS tumours 
were available on the WHO mortality database.   
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Figure 4-23. Trend in incidence by sex: D42-D43 Tumours of uncertain behaviour of brain, meninges & CNS 
 
 CASE COUNT AND TREND AGE-STANDARDISED RATE & TREND, PER 100,000 
IN
C
ID
EN
C
E 
  
 SEX PERIOD APC 95%CI TREND 
MALE 1994-2014 7.0 [4.8,9.1] ↑ 
FEMALE 1994-2014 9.6 [7.2,12.1] ↑ 
 
SEX PERIOD APC 95%CI TREND 
MALE 1994-2014 5.6 [3.5,7.7] ↑ 
FEMALE 1994-2014 8.0 [5.6,10.4] ↑ 
 
 
 
Males: 
 Cases increased significantly during the full period 1994-2014, albeit with low numbers. 
 The incidence rate increased significantly over the same period. 
Females:  
 Cases increased significantly during the full period 1994-2014. 
 The incidence rate increased significantly over the same period. 
  
 Tumours of uncertain morphology for the brain, meninges and CNS are very rare, but there was a significant annual 
increase over the period 1994-2014. This could be an artefact of coding or diagnosis changes: for example, a proportion 
of brain/CNS tumours that would previously have been coded as malignant or as benign might now be appearing in the 
‘uncertain’ category. No mortality data for this group were available on the WHO mortality database.   
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Figure 4-24. Trend in incidence and mortality by sex: C73 Thyroid cancer 
 
 CASE COUNT AND TREND AGE-STANDARDISED RATE & TREND, PER 100,000 
IN
C
ID
EN
C
E 
  
 
 
PERIOD APC 95%CI TREND 
MALE 1994-2014 8.8 [6.9,10.7] ↑ 
FEMALE 1994-2014 10.3 [9.0,11.6] ↑ 
 
 
PERIOD APC 95%CI TREND 
MALE 1994-2014 6.4 [4.6,8.2] ↑ 
FEMALE 1994-2014 8.5 [7.2,9.8] ↑ 
 
M
O
R
TA
LI
TY
 
  
 
 
PERIOD APC 95%CI TREND 
MALE 1994-2013 1.7 [-0.1,3.7] ↔ 
FEMALE 1994-2009 -2.8 [-4.5,-1.1] ↓ 
 
2009-2013 16.7 [2.5,32.8] ↑ 
 
 
PERIOD APC 95%CI TREND 
MALE 1994-2013 -0.4 [-2.2,1.5] ↔ 
FEMALE 1994-2009 -4.7 [-6.6,-2.9] ↓ 
 
2009-2013 12.4 [-2.3,29.5] ↔ 
 
 
 
Males: 
 Cases increased steeply during the full period 1994-2014. 
 The incidence rate increased significantly over the same period. 
 Deaths increased over the full period 1994-2013, albeit from a low base of only 9 deaths per year. 
 The mortality rate was static over the full period 1994-2013.  
Females:  
 Cases increased steeply during the full period 1994-2014 with 2-3 times more cases overall in females relative to males. 
 The incidence rate increased significantly over the same period. 
 Deaths increased significantly over the period 2009-2013 after an earlier period of decrease. 
 The mortality rate showed a marginal increase during 2009-2013 after an earlier period of decrease since 1994. 
 
 Incidence trends for this cancer are likely to reflect an increase in ‘incidental’ detection of cancers during investigations 
for other thyroid-related conditions. 
 Radiation exposure and having a first-degree relative (parent, brother, sister, or child) with thyroid cancer are known 
risk factors for thyroid cancer. Sources of radiation include certain medical treatments or diagnostic radiography 
procedures, and radiation fallout from power plant accidents. 
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Figure 4-25. Trend in incidence and mortality by sex: C81 Hodgkin lymphoma 
 
 CASE COUNT AND TREND AGE-STANDARDISED RATE & TREND, PER 100,000 
IN
C
ID
EN
C
E 
  
 
 
PERIOD APC 95%CI TREND 
MALE 1994-2014 3.7 [2.9,4.5] ↑ 
FEMALE 1994-2014 3.6 [2.3,4.8] ↑ 
 
 
PERIOD APC 95%CI TREND 
MALE 1994-2014 2.2 [1.4,3.0] ↑ 
FEMALE 1994-2014 2.3 [1.0,3.6] ↑ 
 
M
O
R
TA
LI
TY
 
  
 
 
PERIOD APC 95%CI TREND 
MALE 1994-2013 -2.5 [-4.4,-0.5] ↓ 
FEMALE 1994-2013 1.1 [-1.4,3.7] ↔ 
 
 
PERIOD APC 95%CI TREND 
MALE 1994-2013 -4.4 [-6.4,-2.4] ↓ 
FEMALE 1994-2013 -1.1 [-3.6,1.4] ↔ 
 
 
 
Lymphomas are a heterogeneous group of cancers of the haematopoietic system, and can broadly be classified into Hodgkin 
and non-Hodgkin lymphomas based on histological appearance. Hodgkin lymphoma occurs predominantly in younger 
persons (median age 38 during 2012-2014) 
Males: 
 Cases increased significantly during the full period 1994-2014. 
 The incidence rate increased significantly over the same period. 
 Deaths declined during 1994-2013 from a low base of only 15 in 1994. 
 The mortality rate decreased significantly over the full period 1994-2013. 
Females:  
 Cases increased significantly during the full period 1994-2014. 
 The incidence rate increased significantly over the same period. 
 Numbers of deaths were static during the full period 1994-2013. 
 The mortality rate was static over the same period. 
 
 In general, the risk factors for Hodgkin lymphoma are poorly known, but risk is higher among people who have had 
infectious mononucleosis, an infection caused by Epstein-Barr virus. Higher risk of HL among populations with higher 
socioeconomic status might be associated with children from more affluent families being exposed to some type of 
infection (such as Epstein-Barr virus) later in life than children from less affluent families.  
48
88
37
73
0
20
40
60
80
100
1
9
9
4
1
9
9
5
1
9
9
6
1
9
9
7
1
9
9
8
1
9
9
9
2
0
0
0
2
0
0
1
2
0
0
2
2
0
0
3
2
0
0
4
2
0
0
5
2
0
0
6
2
0
0
7
2
0
0
8
2
0
0
9
2
0
1
0
2
0
1
1
2
0
1
2
2
0
1
3
2
0
1
4
0
1
2
3
4
5
1
9
9
4
1
9
9
5
1
9
9
6
1
9
9
7
1
9
9
8
1
9
9
9
2
0
0
0
2
0
0
1
2
0
0
2
2
0
0
3
2
0
0
4
2
0
0
5
2
0
0
6
2
0
0
7
2
0
0
8
2
0
0
9
2
0
1
0
2
0
1
1
2
0
1
2
2
0
1
3
2
0
1
4
15
15
12
9
0
20
40
60
80
100
1
99
4
1
99
5
1
99
6
1
99
7
1
99
8
1
99
9
2
00
0
2
00
1
2
00
2
2
00
3
2
00
4
2
00
5
2
00
6
2
00
7
2
00
8
2
00
9
2
01
0
2
01
1
2
01
2
2
01
3
0
1
2
3
4
5
1
99
4
1
99
5
1
99
6
1
99
7
1
99
8
1
99
9
2
00
0
2
00
1
2
00
2
2
00
3
2
00
4
2
00
5
2
00
6
2
00
7
2
00
8
2
00
9
2
01
0
2
01
1
2
01
2
2
01
3
Page | 40  
 
Figure 4-26. Trend in incidence and mortality by sex: C82-85 All non-Hodgkin lymphoma 
 
 CASE COUNT AND TREND AGE-STANDARDISED RATE & TREND, PER 100,000 
IN
C
ID
EN
C
E 
  
 
 
PERIOD APC 95%CI TREND 
MALE 1994-2014 4.1 [3.7,4.5] ↑ 
FEMALE 1994-2014 3.8 [3.2,4.4] ↑ 
 
 
PERIOD APC 95%CI TREND 
MALE 1994-2014 1.7 [1.3,2.1] ↑ 
FEMALE 1994-2014 1.7 [1.1,2.3] ↑ 
 
M
O
R
TA
LI
TY
 
  
 
 
PERIOD APC 95%CI TREND 
MALE 1994-2013 1.1 [0.2,2.0] ↑ 
FEMALE 1994-2013 1.3 [0.3,2.4] ↑ 
 
 
PERIOD APC 95%CI TREND 
MALE 1994-2013 -1.3 [-2.2,-0.3] ↓ 
FEMALE 1994-2013 -1.0 [-2.1,0.1] ↔ 
 
 
 
Non-Hodgkin lymphoma cases are diagnosed at almost five times the frequency of Hodgkin lymphoma, and have a higher 
median age at diagnosis (66 years during 2012-2014).  
Males: 
 Cases increased significantly during the full period 1994-2014. 
 The incidence rate increased significantly over the same period. 
 Deaths increased significantly during the full period 1994-2013.  
 The mortality rate declined significantly over the same period. 
Females:  
 Cases increased significantly during the full period 1994-2014. 
 The incidence rate increased significantly over the same period. 
 Deaths increased over the full period 1994-2013.  
 The mortality rate was static or showed a marginal decline over the same period. 
 
 As with Hodgkin lymphoma, risk factors for NHL have not been well established, but some types of infection seem to 
increase the risk. 
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Figure 4-27. Trend in incidence and mortality by sex: C90 Multiple myeloma & malignant plasma cell neoplasms 
 
 CASE COUNT AND TREND AGE-STANDARDISED RATE & TREND, PER 100,000 
IN
C
ID
EN
C
E 
  
 SEX PERIOD APC 95%CI TREND 
MALE 1994-2014 2.6 [2.0,3.3] ↑ 
FEMALE 1994-2014 1.8 [0.8,2.8] ↑ 
 
SEX PERIOD APC 95%CI TREND 
MALE 1994-2014 0.3 [-0.3,0.9] ↔ 
FEMALE 1994-2014 0.0 [-1.0,1.0] ↔ 
 
M
O
R
TA
LI
TY
 
  
 
 
PERIOD APC 95%CI TREND 
MALE 1994-2013 1.0 [0.3,1.6] ↑ 
FEMALE 1994-2013 0.7 [-0.2,1.7] ↔ 
 
 
PERIOD APC 95%CI TREND 
MALE 1994-2013 -1.4 [-2.0,-0.8] ↓ 
FEMALE 1994-2013 -1.6 [-2.6,-0.5] ↓ 
 
 
 
Multiple myeloma is a cancer of plasma cells (immunoglobulin-producing B-lymphocytes), where abnormal plasma cells 
accumulate in the bone marrow and interfere with haematopoiesis.  
Males: 
 Cases increased significantly during the full period 1994-2014. 
 The incidence rate was static over the same period. 
 Deaths increased significantly during the full period 1994-2013. 
 The mortality rate declined significantly over the same period. 
Females:  
 Cases increased significantly during the full period 1994-2014. 
 The incidence rate was static over the same period. 
 Deaths increased marginally over the full period 1994-2013. 
 The mortality rate declined significantly over the same period.  
 
 The risk factors for multiple myeloma are poorly understood. 
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Figure 4-28. Trend in incidence and mortality by sex: C91-95 Leukaemia (all sub-classifications combined) 
 
 CASE COUNT AND TREND AGE-STANDARDISED RATE & TREND, PER 100,000 
IN
C
ID
EN
C
E 
  
 
 
PERIOD APC 95%CI TREND 
MALE 1994-2006 4.4 [3.0,5.8] ↑ 
 
2006-2014 -1.1 [-3.3,1.1] ↔ 
FEMALE 1994-2014 1.5 [0.7,2.4] ↑ 
 
 
PERIOD APC 95%CI TREND 
MALE 1994-2004 3.4 [1.6,5.3] ↑ 
 
2004-2014 -3.0 [-4.5,-1.4] ↓ 
FEMALE 1994-2010 0.7 [-0.4,1.8] ↔ 
 
2010-2014 -6.7 [-14.4,1.8] ↔ 
 
M
O
R
TA
LI
TY
 
  
 
 
PERIOD APC 95%CI TREND 
MALE 1994-2004 4.7 [2.4,7.0] ↑ 
 2004-2010 -4.0 [-9.3,1.6] ↔ 
 2010-2013 9.4 [-3.7,24.3] ↔ 
FEMALE 1994-1999 6.9 [-0.4,14.7] ↔ 
 1999-2013 -0.6 [-2.0,0.7] ↔ 
 
 
PERIOD APC 95%CI TREND 
MALE 1994-2004 2.9 [0.7,5.1] ↑ 
 2004-2010 -6.8 [-11.7,-1.5] ↓ 
 2010-2013 6.0 [-6.2,19.8] ↔ 
FEMALE 1994-2013 -1.4 [-2.5,-0.3] ↓ 
 
 
Males: 
 The case count increased significantly during 1994-2006, thereafter it declined non-significantly during 2006-2014. 
 The incidence rate increased during 1994-2004 and then declined significantly during 2004-2014. 
 Deaths showed a complex trend (significant increase 1994-2004 then periods of non-significant decline and increase). 
 The mortality rate increased significantly during 1994-2004, followed by a significant decline during 2004-2010 then a 
non-significant increase during 2010-2014. 
Females:  
 Cases increased significantly during the full period 1994-2014. 
 The incidence rate was static (or showed a marginal increase) over the period 1994-2010, followed by a non-significant 
decline during 2010-2014, later than the decline seen for males. 
 Deaths increased marginally during 1994-1999 followed by a marginal decline during 1999-2013.  
 The mortality rate declined significantly during 1994-2013. 
 
 Risk factors for leukaemia are poorly understood, but some of the strongest evidence is for an influence of smoking and 
exposure to certain chemicals (e.g. benzene) on risk of acute myeloid leukaemia. 
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 Trends in mortality rates showed some similarities to those in incidence rates, but possible artefactual influences on the 
leukaemia incidence trends are explored below, by reference to a specific subtype (CLL).  
 
Figure 4-29. Trend in incidence by sex: C911 Chronic lymphocytic leukaemia (CLL) 
 
 CASE COUNT AND TREND AGE-STANDARDISED RATE & TREND, PER 100,000 
IN
C
ID
EN
C
E 
  
 
 
PERIOD APC 95%CI TREND 
MALE 1994-2006 6.5 [4.0,8.9] ↑ 
 
2006-2014 -3.3 [-6.9,0.5] ↔ 
FEMALE 1994-2009 3.2 [0.8,5.7] ↑ 
 
2009-2014 -9.6 [-20.7,3.2] ↔ 
 
 
PERIOD APC 95%CI TREND 
MALE 1994-2006 4.5 [2.0,7.0] ↑ 
 
2006-2014 -6.2 [-9.8,-2.5] ↓ 
FEMALE 1994-2009 1.8 [-0.6,4.4] ↔ 
 
2009-2014 -12.2 [-23.5,0.9] ↔ 
 
 
 
Figure 4-30. Trend in incidence by sex: C91-95 Leukaemia excluding C911 Chronic lymphocytic leukaemia (CLL) 
 
 CASE COUNT AND TREND AGE-STANDARDISED RATE & TREND, PER 100,000 
IN
C
ID
EN
C
E 
  
 
 
PERIOD APC 95%CI TREND 
MALE 1994-2014 1.9 [1.3,2.6] ↑ 
FEMALE 1994-2014 1.8 [0.9,2.8] ↑ 
 
 
PERIOD APC 95%CI TREND 
MALE 1994-2014 -0.2 [-0.8,0.5] ↔ 
FEMALE 1994-2014 0.1 [-0.9,1.0] ↔ 
 
 
 
 Chronic lymphocytic leukaemia (CLL), which accounted for 41% of registered leukaemia cases in 1994 and 36% in 2014, 
showed evidence of a recent decrease in case counts and incidence rate for both sexes (Figure 4-29). 
 If CLL cases were excluded, case counts of other leukaemias showed increases throughout 1994-2014 and incidence 
rates remained static, in both sexes. 
 Trends shown by leukaemias as a whole (in particular, recent declines in incidence) therefore appeared to be heavily 
influenced by trends in CLL. 
 Whether this reflects a real decline in CLL, or a failure in case ascertainment somewhere along the diagnostic pathway, 
remains to be confirmed. However, it is possible that an increase in outpatient or GP-initiated diagnosis of CLL in recent 
years may have resulted in under-registration of CLL, and efforts are currently underway to remedy this. 
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5. PREVALENCE: NUMBERS OF CANCER SURVIVORS 
 
For the purposes of this report cancer prevalence was defined as the number of cancer survivors that were alive on 31st 
December 2014. This is the date to which follow-up of all registered cancer patients (through matching of registrations to 
death certificates) is currently complete. 
Total prevalence could not be estimated as information on patients diagnosed before 1994 (the first year of national cancer 
registration in Ireland) was not available. However, period prevalence for 1994-2014 was defined as the number of cancer 
survivors who had at least one invasive cancer (other than non-melanoma skin cancer) diagnosed during 1994-2014 who 
were still alive on 31st December 2014. Period prevalence for shorter diagnosis periods was also defined for some analyses. 
 
Figure 5-1.  Summary characteristics of 139,526 cancer survivors* in Ireland on 31st December 2014 
   
SEX incidence alive % 
females 153,662 71,062 46 
males 168,520 68,464 41 
all 322,182 139,526 43 
 
AGEa incidence alive % 
<45 31,504 23,562 75 
45-59 70,232 43,072 61 
60-74 127,946 55,667 44 
75+ 92,500 17,225 19 
 
HSE AREAb incidence alive % 
DNML 90,461 40,512 45 
DNNE 65,085 28,184 43 
SOUTH 85,682 36,458 43 
WEST 80,954 34,372 42 
 
*C00-C43, C45-C96 all invasive cancers, excluding NMSC diagnosed 1994-2014, counting only the first invasive cancer per patient. 
aAge at diagnosis. bHSE area of residence at diagnosis, DNML (Dublin mid Leinster), DNNE (Dublin north-east). 
 
 During 1994-2014, a total of 322,182 persons (153,662 females and 168,520 males) were diagnosed with invasive 
cancer (Figure 5-1). 
 Of these, 139,526 patients were still alive at the end of 2014, representing the period prevalence of cancer survivors for 
1994-2014.  
 This represents 46% of all females and 41% of males diagnosed with cancer since 1994, or 3% of the total Irish 
population of 4.6 million in 2014. 
 There were marginally more female cancer survivors (51% of total) than males (49%).  
 52% of cancer survivors were over 60 years, 17% were less than 45 years at the time of their first cancer diagnosis.  
 Of the four HSE areas, Dublin/Mid-Leinster held the highest proportion of cancer survivors (29%). However HSE West 
and HSE South combined held marginally more survivors (51%) than the two eastern regions combined 
 139,526 is a conservative estimate of total cancer prevalence, as it excludes relatively small numbers of other cancer 
survivors who were diagnosed more than 21 years ago, before NCR data collection began. Total prevalence is likely to 
exceed 150,000 cancer survivors, and an estimate of this number will be presented in 2017. A breakdown of cancer 
prevalence by cancer site is presented below (Figures 5-2 and, by cancer site and sex, Figure 5-3).  
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Figure 5-2.  Site-specific cancer prevalence: number of cancer survivors on 31st December 2014, males and 
females combined, for the most common cancers (excluding NMSC)
 
Each patient is counted once for each specific type of cancer they have survived, i.e. some patients are included as survivors of more 
than one cancer type. Not all cancer sites are shown. 
‡Other gynaecological: vulva, vagina, placenta and uterus NOS. 
 
 The number of survivors of a given cancer type is related to its incidence rate, its median age at diagnosis and its 
survival prospects. Rare, high-fatality cancers diagnosed in the elderly comprise only a small proportion of cancer 
survivors. Conversely, common cancers diagnosed in younger persons with good survival prospects will tend to 
predominate in the prevalent cancer population. 
 Overall, the top six most common cancers in the prevalent cancer population were: breast cancer (previously diagnosed 
in 23% of all cancer survivors), prostate (22%), colorectal (12%), skin melanoma (7%), non-Hodgkin lymphoma (4%) and 
lung cancer (3%) (Figure 5-2). These percentages are not mutually exclusive, as some cancer survivors had survived 
more than one type of cancer. 
 Less common, high-fatality cancers such as liver, pancreatic, oesophageal and stomach cancers and multiple myeloma 
and stomach cancer together comprise only 4% of the prevalent population. 
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Figure 5-3. Site-specific cancer prevalence: number of cancer survivors on 31st December 2014, by sex, for the 
most common  cancers (excluding NMSC) 
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Each patient is counted once for each specific type of cancer they have survived, i.e. some patients are included as survivors of more than 
one cancer type. Not all cancer sites are shown. 
*Other gynaecological: vulva, vagina, placenta and uterus NOS.  
 
 The top five most common prevalent cancers in females were: breast cancer (previously diagnosed in 44% of all female 
cancer survivors), colorectal cancer (11%), skin melanoma (8%), uterine (6%) and cervical cancer (4%). Again, it should 
be noted that these percentages are not mutually exclusive, as some cancer survivors had survived more than one type 
of cancer. 
 The top five most common prevalent cancers in males were prostate cancer (45% of all male cancer survivors), 
colorectal cancer (14%), skin melanoma (5%), non-Hodgkin lymphoma (5%) and testicular cancer (4%).  
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One way of looking at cancer prevalence is to consider the proportion of patients from consecutive diagnosis periods still 
alive at the end of 2014, for each cancer (Figure 5-4). This approach illustrates how age at diagnosis, survivability and cancer 
type interact to shape the prevalent population. Generally, the height of the bars reflects the relative survivability for each 
cancer, or conversely (short bars) their relative lethality. 
 
Figure 5-4. Percentage of incident cases alive at 31/12/2014 for five discrete diagnosis periods, by site 
 
 
The legend represents the diagnosis period e.g. 2013-2014 (0-2) refers to the period up to 2 years before 31/12/2014.  
Displayed percentages refer to the proportion of cases alive for each cancer type diagnosed during 1994-1999.  
‡Other gynae: vulva, vagina, placenta and uterus NOS.  Each patient is counted once for each specific type of cancer they have survived, i.e. 
some patients are included as survivors of more than one cancer type. Sorted on the percentage alive for the period 1994-1999. 
Page | 48  
 
 For all cancers combined (excl. NMSC), almost 80% of those diagnosed in the latest period 2013-2014 (0-2 years before 
31/12/2014) were alive, compared with 61% of those diagnosed 2010-2012 (within 2-5 years of 31/12/2014), compared 
to 47% of those diagnosed during 2005-2009 (5-10 years before 31/12/2014), and 32% of those diagnosed 2000-2004 
(10-15 years before 31/12/2014). Finally, only 20% of those diagnosed during the earliest period 1994-1999 (>15 years 
before 31/12/2014) were still alive. 
 Pancreatic cancer was the 9th most common incident cancer overall (Fig 2-2). Of those diagnosed 0-2 years before 
31/12/2014, only 33% remained alive. Of those diagnosed 2-5 years before 31/12/2014, only 9% remained alive. Of 
those diagnosed >15 years before 31/12/2014, only 2% remained alive. 
 Lung cancer was the 4th most common cancer overall (Fig 2-2). Of those diagnosed 0-2 years before 31/12/2014, only 
45% remained alive. Of those diagnosed 2-5 years before 31/12/2014, only 17% remained alive. Of those diagnosed >15 
years before 31/12/2014, only 3% remained alive. 
 Primary liver cancer is rare. Of those diagnosed 0-2 years before 31/12/2014, only 43% remained alive. Of those 
diagnosed 2-5 years before 31/12/2014 only 21% remained alive. Of those diagnosed >15 years before 31/12/2014, 
only 4% remained alive. 
 Oesophageal and stomach cancer were the 13th and 8th most common incident cancers diagnosed overall (Fig 2-2). Of 
those diagnosed >15 years before 31/12/2014, only 4% and 6% remained alive respectively. 
 Multiple myeloma is a relatively rare tumour mostly confined to the elderly. Of those diagnosed 0-2 years before 
31/12/2014, 81% remained alive, which was relatively high. However, of those diagnosed >15 years before 31/12/2014, 
only 6% remained alive, in part reflecting the high median age at diagnosis for this cancer influencing overall mortality in 
the earlier diagnostic periods. 
 Prostate cancer was the most common cancer overall with a high median age at diagnosis (Fig 2-2). Of those diagnosed 
0-2 years before 31/12/2014, 96% remained alive. However, of those diagnosed >15 years before 31/12/2014, only 6% 
remained alive, again probably due to the high median age at diagnosis for this cancer influencing overall mortality in 
the earlier diagnostic periods. 
 At the other end of the spectrum, testicular cancer is relatively uncommon and tends to occur in younger men. Of those 
diagnosed 0-2 years before 31/12/2014, 99% were alive. Of those diagnosed >15 years before 31/12/2014, 85% were 
alive which illustrates the excellent survival prospects, combined with younger age at diagnosis, for this cancer 
compared to most other cancers (Figure 5-4). 
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Persons diagnosed in earlier years, especially if diagnosed with a rare or relatively lethal cancer (e.g. pancreatic cancer) or at 
an older age, were less likely to form part of the overall prevalent cancer population (Figure 5-5).  
 
Figure 5-5. Numbers of cancer survivors at 31/12/2014, by diagnosis period  
 
 
Counting only the first invasive cancer per patient. The legend represents diagnosis period, e.g. 2013-2014 (0-2) refers to the period up to 2 years 
before 31/12/2014. Sorted on displayed number of cases for each site diagnosed during 1994-1999 (>15 years before 31/12/2014), e.g. only 39 
living persons were diagnosed with pancreatic cancer as far back as 1994-1999, or 6% (39/659) of all known pancreatic cancer survivors. 
Other gynae‡: vulva, vagina, placenta and uterus NOS. 
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 Patients diagnosed during 1994-1999 (15-21 years before 31/12/2014) comprised the smallest group of cancer survivors 
(14,662 of 139,526, 11%), as might be expected due to the elapsed time since diagnosis (upper panel, Fig. 5-5). 
 101,860 patients diagnosed during 2005-2014 (up to 10 years before 31/12/2014) comprised the majority (73%) of the 
prevalent population. 
 63,329 patients diagnosed during 2010-2014 (up to 5 years prior to 31/12/2014) made up 45% of the prevalent 
population; this group can be considered broadly equivalent to persons undergoing initial treatment or follow-up 
clinical surveillance. 
 The 29,285 patients diagnosed during 2013-2014 made up 21% of the prevalent population, and in broad terms 
comprise the group in the intensive treatment phase and beginning of follow-up (upper panel, Fig. 5-5). 
 
The breakdown by diagnosis period for each individual cancer (lower panel Fig. 5-5) varies from that observed in the overall 
picture (upper panel Fig. 4-5) and illustrates how cancer type, survival prospects and average age of diagnosis influence the 
make-up of the cancer survivor population. Looking specifically at cancer survivors from >15 years ago (from 1994-1999): 
 Breast cancer, the most prevalent cancer overall, has relatively good survival prospects; as might be expected, the 
largest number of cancer survivors diagnosed during the earliest period (1994-1999): were breast cancer survivors 
(3,815, or 11% of 31,655 breast cancer survivors). 
 Colorectal cancer, the third most prevalent cancer, has moderately good survival prospects and comprised the second 
highest number of survivors from 1994-1999 (1,933, or 11% of 17,136 colorectal cancer survivors). 
 Melanoma, the fourth most prevalent cancer, has relatively good survival prospects and comprised the third highest 
number of survivors from 1994-1999 (1,171, or 13% of 9,254 melanoma survivors).  
 Prostate cancer, the second most prevalent cancer overall, has fairly good survival prospects, although they were 
markedly less men surviving from the earliest period due older age at diagnosis (median 66y); the fourth highest 
number of survivors from 1994-1999 were prostate cancer patients (1,146, or 4% of 30,462 prostate cancer survivors). 
 Bladder cancer, the fifth most prevalent cancer, also has fairly good survival prospects, and comprised the fifth highest 
number of survivors from this earliest period (667, or 18% of 3,659 bladder cancer survivors). Of all the prevalent 
cancers, bladder cancer has the highest proportion of long term survivors (followed by testis (17%), and Hodgkin 
lymphoma (17%), although this may be over-estimated because of coding issues (non-invasive bladder tumours 
miscoded as invasive). 
 At the other end of the spectrum, pancreas is an uncommon cancer with poor survival prospects. Not surprisingly, it 
made up only a small proportion of the prevalent cancer population; 352 (53%) were diagnosed within 2 years before 
31/12/2014 and only 39 (6%) were diagnosed more than 15 years in the past. 
 Similarly, even though lung cancer was the sixth most prevalent cancer, only 270 (6%) of all lung cancer survivors were 
diagnosed in the earliest period (lower panel Fig. 5-5). 
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Although many cancer survivors can be considered cured or disease-free, some may experience recurrences of their original 
cancer, metastatic spread to other body sites, or further primaries of the same body site (e.g. bladder), or may have health 
conditions related to their previous cancer treatment. Other survivors may go on to be diagnosed with other, different 
primary cancers, sometimes because of common risk factors (e.g. smoking) across different cancer types, sometimes related 
to previous cancer treatment, and sometimes by chance (especially in longer-term survivors). 
Figure 5-6 and Table 5-1 (below) summarises for cancer survivors the proportion of patients who have been diagnosed with 
more than one cancer in a different body system e.g. colon cancer subsequent to breast cancer. This is a somewhat different 
scenario to patients who may have had multiple sequential tumours of the same type or recurrences of the original cancer. 
Where different cancers are involved, the patient may undergo very different treatment and follow-up protocols, and the 
healthcare resources involved and psychosocial or other impacts on the survivor, are likely to be substantial. 
 
Figure 5-6. Numbers of cancer survivors at 31st December 2014, by sex, showing the proportion diagnosed with 
primary cancers of more than one body site during 1994-2014 
 
 
 
SEX 
PREVALENCE 
31/12/2014 
males   68,464  
females   71,062  
all  139,526  
 
 
Top portion of graph bars (orange) represent the percentage of survivors diagnosed with more than one cancer (excluding recurrence, 
metastases, multiple tumours at the same body site, or NMSC) 
 
 Of the prevalent population on 31/12/2014, 6,520 (4.7%) had been diagnosed with more than one distinct cancer type 
since 1994 (5.3% of males, 4.0% of females).  
 Inclusion of all second or subsequent primaries (including those of the same site) would increase this only slightly, to 
4.9%. 
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Table 5-1. Numbers of cancer survivors at 31st December 2014, by sex, diagnosed with more than one cancer at 
a different body site during 1994-2014 
MALES  FEMALES  MALES AND FEMALES 
site >1 other  
cancer 
%  site >1 other  
cancer 
%  site >1 other  
cancer 
% 
bladder             292  12.1%  small intestine               12  7.7%  bladder             345  10.1% 
kidney             184  8.6%  ovary             149  7.3%  larynx               95  8.4% 
larynx               82  8.6%  larynx               13  7.3%  ovary             149  7.3% 
mouth & pharynx             112  7.7%  corpus uteri             277  7.1%  kidney             248  7.1% 
breast               14  7.7%  other gynaecological†               43  6.2%  corpus uteri             277  7.0% 
colorectum             618  6.9%  stomach               36  5.4%  other gynaecological†               43  6.7% 
stomach               72  6.8%  bladder               53  5.1%  mouth & pharynx             148  6.4% 
small intestine               13  5.7%  kidney               64  4.8%  stomach             108  6.2% 
lymphoma             210  5.5%  colorectum             337  4.7%  colorectum             955  6.0% 
other             211  5.5%  lymphoma             165  4.7%  small intestine               25  5.3% 
oesophagus               32  5.4%  oesophagus               17  4.6%  lymphoma             375  5.2% 
skin melanoma             177  5.2%  other             134  4.5%  other             345  5.1% 
lung             101  4.9%  mouth & pharynx               36  4.4%  oesophagus               49  5.1% 
leukaemia             108  4.8%  skin melanoma             232  4.3%  skin melanoma             409  4.7% 
thyroid               21  4.5%  pancreas               13  4.2%  prostate          1,306  4.4% 
prostate          1,306  4.4%  lung               84  3.9%  lung             185  4.3% 
liver               13  4.0%  multiple myeloma               18  3.4%  leukaemia             157  4.1% 
multiple myeloma               26  3.5%  breast             985  3.2%  multiple myeloma               44  3.5% 
bone                 3  2.3%  leukaemia               49  3.1%  pancreas               18  3.4% 
mesothelioma                 1  2.3%  bone                 3  3.1%  liver               15  3.3% 
testis               48  1.8%  cervix uteri               93  3.0%  breast             999  3.2% 
pancreas                 5  1.7%  thyroid               42  2.5%  cervix uteri               93  3.1% 
brain and CNS                 6  0.8%  liver                 2  1.6%  thyroid               63  3.0% 
    brain and CNS                 8  1.3%  bone                 6  2.6% 
    mesothelioma                0    0.0%  mesothelioma                 1  1.9% 
        testis               48  1.8% 
        brain and CNS               14  1.0% 
Total          3,655  5.3%  Total          2,865  4.0%  Total          6,520  4.7% 
Selecting on first cancer diagnosed and counting other cancers diagnosed at differerent body site(s) thereafter up to end of 2014 
†Other gynaecological: vulva, vagina, placenta and uterus NOS 
‘>1 other cancer’ represents the number of persons with that cancer also diagnosed with a primary cancer cancer (excluding NMSC) at 
another body site on a subsequent (or the same) date. 
The percentage represents the proportion that that number represents of all cancer survivors whose first cancer was at a given site. 
Example: 292 (12% of) survivors of bladder cancer in males were also diagnosed with of at least one other cancer at a differerent body site, 
typically occurring in other sites sharing the same risk factors as bladder cancer (e.g. kidney cancer). 
 
 While cancer of the bladder was uncommon, 10% of the total number of survivors of this cancer also had at least one 
other cancer at another body site.  
 A high proportion (8.4%) of survivors of laryngeal cancer also experienced diagnoses of other cancers, mostly of nearby 
body systems (e.g. lung, oesophagus and mouth/pharynx – details of other cancers not shown). 
 Of the most common cancers in the prevalent population, 955 colorectal cancer survivors, or 6% of all colorectal cancer 
survivors, had diagnoses of other primary cancers.  
 1,306 prostate cancer survivors, or 4.4% of all prostate cancer survivors, had other cancer diagnoses, such as bladder 
cancer. 
 999 breast cancer survivors, or 3.2% of all breast cancer survivors, also had other cancer diagnoses. 
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6. SURVIVAL  
 
Net survival estimates to five years and ten years are presented here for cancer as a whole (excluding non-melanoma skin 
cancer) and for the most frequent cancers (Figures 6-1 to 6-5). Ten-year estimates have not been published formally by the 
NCR previously. Net survival is calculated by comparing the observed survival of patients with the expected survival of 
persons of the same age and sex in the general population. It represents the cumulative probability of a patient surviving a 
given time in the hypothetical situation in which the disease of interest is the only possible cause of death, i.e. survival having 
controlled for other possible causes of death [16]. Actual (observed) survival will generally be lower than net survival, 
especially in older age-groups, reflecting deaths from other causes, although for high-fatality cancers and in younger age-
groups most deaths among cancer patients will be related to the cancer (Figures 6-6 to 6-9). 
 
Figure 6-1  Estimates of 5-year and 10-year net survival (age-standardised) for invasive cancers in Ireland, 2010-2014 
 
‘Hybrid’ estimates are presented here for the follow-up period 2010-2014, representing survival of one-year to five-year survival for 
cases diagnosed in 2013 back to 2009 supplemented by longer-term follow-up survival estimates of patients diagnosed pre-2009 using 
methods of Dickman et al. [16]. 
Survival for all ages 15-99 is standardised to the standard populations recommended by Corazziari et al. (2004); the age-groups used 
differ for prostate cancer, and greater weighting is given to younger patients for melanoma, reflecting differences in typical age-
structure of patient populations for these cancers) [17]. 95% confidence intervals are shown 
 
 The cancer sites with the highest estimated 10-year net survival were testis (96%), prostate (89%), skin melanoma (86%) 
and breast (75%). 
 The cancer sites with the lowest 10-year survival were pancreas (<8%), liver (11%), lung (15%) and oesophagus (18%). 
 Survival for specific age-groups is summarised in Appendix IV. 
 
Survival trends for cancer as a whole and colorectal, lung, breast and prostate cancers are summarised in Figures 6-2 to 6-5 
below, and age-specific estimates of net and observed survival are compared for the same cancers in Figures 6-6 to 6-9. 
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Figure 6-2. Age-standardised 5-year and 10-year net survival (with 95% confidence intervals) for all cancers 
excluding NMSC, by diagnosis period 
 
ALL CANCERS (BOTH SEXES) ALL CANCERS (MALE) ALL CANCERS (FEMALE) 
   
 ‘Hybrid’ estimate for 2010-2014 [16] 
  
 Five-year net survival for cancers as a whole (excluding non-melanoma skin cancers) increased from 44% for patients 
diagnosed during 1994-1998 to 61% for those diagnosed during 2009-2013, for male and female patients combined. 
 Ten-year survival increased from 40% (1994-1998) to 53% (2004-2008); sufficient follow-up is not yet available for the 
2009-2013 cohort, but a ‘current’ estimate of 57% ten-year survival is available for the 2010-2014 follow-up period 
(taking account of all patients alive in the most recent years). 
 Males and females showed similar patterns of survival improvement over time, although net survival averaged slightly 
higher among males than females throughout (reflecting differences in cancer types involved and the higher average 
age of females compared with males in the oldest age-group, 75+ years). 
 
Figure 6-3. Age-standardised 5-year and 10-year net survival (with 95% confidence intervals) for colorectal 
cancer, by diagnosis period 
 
COLORECTAL CANCER (BOTH SEXES) COLORECTAL CANCER (MALE) COLORECTAL CANCER (FEMALE) 
   
 
 
 Five-year net survival from colorectal cancer increased from 50% during 1994-1998 to 63% during 2009-2013. 
 Ten-year survival increased from 46% (1994-1998) to 53% (2004-2008), and the most recent estimate is 57%, based on 
all patients followed up during 2010-2014. 
 Males and females showed similar improvements over time, although net survival from colorectal cancers averaged 
slightly higher among females in most periods. 
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Figure 6-4.  Age-standardised 5-year and 10-year net survival (with 95% confidence intervals) for lung cancer, 
by diagnosis period 
 
LUNG CANCER (BOTH SEXES) LUNG CANCER (MALE) LUNG CANCER (FEMALE) 
   
Cancer of the trachea is included 
 
 Five-year net survival from lung cancer approximately doubled from 9% during 1994-1998 to 18% during 2009-2013. 
 Ten-year survival increased from 7.5% (1994-1998) to 10% (2004-2008), and the most recent estimate is 15%, based on 
all patients followed up during 2010-2014. 
 Both males and females showed improvements over time, but improvements seem to have been more marked among 
female lung cancer patients, whose average survival has been markedly higher than that of males after 1999. 
 
Figure 6-5. Age-standardised 5-year and 10-year net survival for breast 
and prostate cancer, by diagnosis period 
 
BREAST CANCER (FEMALE) PROSTATE CANCER 
  
  
 
 Five-year net survival from female breast cancer increased from 72% during 1994-1998 to 83% during 2009-2013. Ten-
year survival increased from 62% (1994-1998) to 73% (2004-2008) and an estimated 75% for 2010-2014. 
 Five-year net survival from prostate cancer increased markedly, from 66% during 1994-1998 to 92% during 2009-2013. 
Ten-year survival increased from 57% (1994-1998) to 88% (2004-2008), and the most recent estimate is 89%, based on 
all patients followed up during 2010-2014. However, improvements seen are partly related to increased detection of 
sub-clinical cancers by PSA testing which can produce an artificial increase in average survival time (lead-time bias). 
 Both breast and prostate cancers show evidence of a recent slowing down in the rate of survival improvement. 
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Although net survival or relative survival is a standard measure of survival likelihood for cancer patients, the actual 
(observed) survival of patients will also reflect the general risk of death among persons of the same age and sex. In younger 
cancer patients, most of the risk of death is associated with the cancer, but in older patients there is also substantial risk of 
death from other causes. Thus there can be a substantial difference between net survival and observed survival for older 
patients, particularly for less fatal cancers. The graphs below illustrate this for the four most important cancer types. 
 
Figure 6-6. Comparison of net survival and observed survival, by age: colorectal cancer, 2010-2014 
 
ALL AGES (AGE-STANDARDISED) AGE 55-64 
  
  
AGE 15-44 AGE 65-74 
  
  
AGE 45-54 AGE 75-99 
  
 
 For colorectal cancer patients, most of the mortality risk is associated with the cancer, but in the oldest group (75+ 
years) a substantial proportion of total deaths among patients are associated with other mortality causes. In this group, 
52% five-year net survival implies that, on average, 48% of patients would be expected to die from their cancer within 
five years (if other causes of death did not apply) but, in fact, 66% of patients die within five years (34% observed 
survival), including deaths from other causes.   
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Figure 6-7. Comparison of net survival and observed survival, by age: lung cancer, 2010-2014 
 
ALL AGES (AGE-STANDARDISED) AGE 55-64 
  
  
AGE 15-44 AGE 65-74 
  
  
AGE 45-54 AGE 75-99 
  
 
 For lung cancer patients, a higher proportion of their mortality risk is associated with the cancer, and even in the oldest  
group (75+ years) only a small proportion of total deaths among patients are associated with other mortality causes. In 
this group, 10% five-year net survival implies that, on average, 90% of patients would be expected to die from their 
cancer within five years (if other causes of death did not apply)  – in fact, 94% of patients die within five years (6% 
observed survival), including deaths from other causes.   
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Figure 6-8. Comparison of net survival and observed survival, by age: female breast cancer, 2010-2014 
 
ALL AGES (AGE-STANDARDISED) AGE 55-64 
  
  
AGE 15-44 AGE 65-74 
  
  
AGE 45-54 AGE 75-99 
  
 
 For breast cancer patients, although most of the mortality risk is still associated with the cancer, a higher proportion of 
deaths are associated with other causes than is the case with colorectal or (especially) lung cancer. In the oldest group 
(75+ years), 71% five-year net survival implies that 29% of patients would be expected to die from their cancer within 
five years (if other causes of death did not apply) but, on average, 53% of patients die within five years (47% observed 
survival), including deaths from other causes.   
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Figure 6-9. Comparison of net survival and observed survival, by age: prostate cancer, 2010-2014 
 
ALL AGES (AGE-STANDARDISED) AGE 65-74 
  
  
AGE 15-54 AGE 75-84 
  
  
AGE 55-64 AGE 85-99 
  
 
 For prostate cancer patients, an even higher proportion of deaths are associated with other causes than is the case for 
breast cancer. In the second oldest group (75-84 years), 84% five-year net survival implies that 16% of patients would be 
expected to die from their cancer within five years (if other causes of death did not apply) but, on average, 41% of 
patients die within five years (59% observed survival), including deaths from other causes.  For the very oldest patients 
(age 85+), other causes of death become even more important.  
 
 In summary, more than half of the deaths (within five years) among prostate cancer patients aged 75 years or more may 
be attributable to non-cancer causes – compared with <50% of deaths for breast cancer patients, <30% of deaths for 
colorectal cancer patients but only about 5% of deaths for lung cancer patients of a similar age.  
 Thus, for cancers of, on average, lower fatality, a high proportion of elderly patients may die with (rather than from) 
their cancer. 
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7. METHODS 
  
The National Cancer Registry was established by the Minister for Health in 1991. It has been collecting comprehensive cancer 
information for the Republic of Ireland since 1994. The information collected is used in research into the causes of cancer, in 
education and information programmes, and in the planning of cancer services to deliver the best cancer care to the whole 
population. Completeness of case ascertainment at five years after diagnosis is estimated to be at least 98% [18]. 
Incidence data are collected and coded by the NCR according to the ICDO3 classification (including translation from ICDO2 
codes for older data) [19]. For convenience, cancer types are specified or grouped in this report under ICD10-type codes, but 
these do not correspond to ‘strict’ ICD10 codes as some neoplasms classed as non-invasive / non-malignant under ICD10 (e.g. 
myelodysplastic syndrome, ICD10 D46) are now considered fully malignant under ICDO3. For such cases, the nearest 
equivalent malignant ICD10 code or subheading is used (thus polycythaemia, myelodysplastic syndromes and chronic 
myeloproliferative diseases have been included under C96, rather than D45-D47).  
Age-, sex- and cause-specific deaths attributable to cancer were downloaded from the WHO website for years 1994 to 2013 
[3]. At the time of compilation of this report, deaths for 2014 (by year of death) were not available. For selected sites, an 
update of the mortality trends presented in the 1994-2012 NCR report [1] are presented. 
 
The age-standardised (ASR) rate is the annual rate of newly 
diagnosed cases (or deaths) in a given population (and year), 
expressed per 100,000 persons (usually males and females 
separately), weighted by the age-structure of a defined 
‘standard’ population, to allow meaningful comparisons 
between different countries over time [21]. By convention for 
European cancer registries, age-standardised rates for incidence 
and mortality were weighted by the European standard 
population (ESP) as defined in 1976 [4]. However, this report 
also presents incidence rates weighted by the 2013 ESP 
proposed by EUROSTAT to more accurately reflect the 
demographic age shift in the European population since 1976 
[20]. The 2013 ESP is a better reflection of the current 
population structure than the ESP of 1976. The 2013 ESP gives 
older ages a greater weight than the 1976 ESP and also, while 
the 1976 ESP has only one upper age band of 85+ years, the 
2013 ESP contains age bands of 85-89, 90-94 and 95+. Like most 
cancer registries, by convention the NCR pools case-counts and 
population weights for age categories ‘<1 year’ and ’01-04 years’ 
(Table 7-1). 
 
 
Annual percentage changes (APC) of incidence/mortality over 
time (incidence 1994-2014/mortality 1994-2013) were estimated with the Joinpoint regression program, using annual age-
standardised rates and their standard errors as inputs [8][9]. The same break point constraints for trend were applied to 
rates calculated using the 1976 ESP and 2013 ESP. Default constraints were used with Joinpoint; a maximum of three trend 
break points where allowed over the 21 year period from 1994-2014, and only after four consecutive years inclusive, and 
four years from either end of the year range (inclusive). 
Table 7-1. Comparison of the 1976 ESP and the  
2013 ESP population structures 
1976 ESP   2013 ESP 
age band weight per  
100,000  
  age band weight per  
100,000  
<1 1600   <1 1000 
01-04 6400   01-04 4000 
05-09 7000   05-09 5500 
10-14 7000   10-14 5500 
15-19 7000   15-19 5500 
20-24 7000   20-24 6000 
25-29 7000   25-29 6000 
30-34 7000   30-34 6500 
35-39 7000   35-39 7000 
40-44 7000   40-44 7000 
45-49 7000   45-49 7000 
50-54 7000   50-54 7000 
55-59 6000   55-59 6500 
60-64 5000   60-64 6000 
65-69 4000   65-69 5500 
70-74 3000   70-74 5000 
75-79 2000   75-79 4000 
80-84 1000   80-84 2500 
85+ 1000   85-89 1500 
      90-94 800 
      95+ 200 
Total 100,000   Total 100,000 
Source: EUROSTAT [20] 
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Survival figures presented in this report use net survival, an 'improved' version of relative survival taking better account of 
competing mortality risks and allowing greater comparability between different populations or age-groups. Net survival 
represents the cumulative probability of a patient surviving a given time in the hypothetical situation in which the disease of 
interest is the only possible cause of death, i.e. survival having controlled for other possible cause of death [16]. (This 
involves comparison of observed survival with the expected survival of persons of the same age and gender in the general 
population, as for relative survival). Net survival was calculated using the ‘strs’ command in STATA with an adjustment to 
obtain the Pohar-Perme estimate. All survival estimates were age-standardised to the International Cancer Survival 
Standards (ICSS) [17].  
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APPENDIX I: SUMMARY TABLE - CANCER INCIDENCE: ANNUAL AVERAGE 2012-2014 
 
ICD10* cancer site (INCIDENCE)  MALES FEMALES  ALL 
N# Average annual number of cases 2012-2014 rounded to nearest integer 
ASR‡ Age-standardised rate/100,000- weighted by ESP~ 1976 and 2013 
Risk† Cumulative risk (%) to age 75 years    ESP~ European Standard Population 
 N# % all 
invasive 
% all 
invasive 
excl. NMSC 
ASR‡ 
ESP~ 
1976 
ASR‡ 
ESP 
2013 
Risk†  
75Y 
N# % all 
invasive 
% all 
invasive 
excl. NMSC 
ASR‡ 
ESP 
1976 
ASR‡ 
ESP 
2013 
Risk† 
 75Y 
 N# % all 
invasive 
% all 
invasive 
excl. NMSC 
C00-96 all invasive cancers   16,618  100%    720.0    1,119.0   44.09   14,054  100%    547.6    794.5   35.21    30,672  100%  
C00-43, C45-96 all invasive cancers, excluding NMSC   11,101  66.8% 100%   483.3    730.6   33.37    9,703  69.0% 100%   384.5    540.6   26.63    20,804  67.8% 100% 
C00-D48 all registered tumours   18,330      793.9    1,233.3   47.26   19,261      754.5    1,032.8   44.59    37,591    
D00-48 all non-invasive tumours**   1,712      73.9    114.4    5.66    5,207      206.9    238.3   14.47    6,919    
C00 lip    19  0.1% 0.2%   0.8    1.3    0.06     5  <0.1% 0.1%   0.2    0.3    0.01    24  0.1% 0.1% 
C01 base of tongue    28  0.2% 0.3%   1.3    1.6    0.11     8  0.1% 0.1%   0.4    0.4    0.03    36  0.1% 0.2% 
C02 other and unspecified parts of tongue    46  0.3% 0.4%   2.1    2.7    0.19    27  0.2% 0.3%   1.1    1.5    0.09    73  0.2% 0.4% 
C03 gum    13  0.1% 0.1%   0.6    0.8    0.05     6  <0.1% 0.1%   0.3    0.3    0.02    19  0.1% 0.1% 
C04 floor of mouth    27  0.2% 0.2%   1.2    1.5    0.11     7  <0.1% 0.1%   0.3    0.4    0.03    34  0.1% 0.2% 
C05 palate    14  0.1% 0.1%   0.6    0.8    0.05     7  <0.1% 0.1%   0.3    0.4    0.02    20  0.1% 0.1% 
C06 other and unspecified parts of mouth    14  0.1% 0.1%   0.6    1.0    0.05    14  0.1% 0.1%   0.6    0.8    0.04    28  0.1% 0.1% 
C07 parotid gland    24  0.1% 0.2%   1.0    1.6    0.08    12  0.1% 0.1%   0.5    0.6    0.03    35  0.1% 0.2% 
C08 other and unspecified major salivary glands    4  <0.1% <0.1%   0.2    0.3    0.02     3  <0.1% <0.1%   0.1    0.1    0.01     7  <0.1% <0.1% 
C09 tonsil    42  0.3% 0.4%   1.9    2.3    0.16    13  0.1% 0.1%   0.5    0.7    0.05    54  0.2% 0.3% 
C10 oropharynx    19  0.1% 0.2%   0.9    1.1    0.08     5  <0.1% 0.1%   0.2    0.3    0.02    24  0.1% 0.1% 
C11 nasopharynx    11  0.1% 0.1%   0.5    0.6    0.04     5  <0.1% 0.1%   0.2    0.3    0.02    16  0.1% 0.1% 
C12 pyriform sinus    26  0.2% 0.2%   1.1    1.6    0.10     3  <0.1% <0.1%   0.1    0.2    0.01    29  0.1% 0.1% 
C13 hypopharynx    15  0.1% 0.1%   0.7    0.9    0.06     4  <0.1% <0.1%   0.2    0.3    0.01    20  0.1% 0.1% 
C14 other and ill-defined sites of lip, oral cavity/pharynx    13  0.1% 0.1%   0.6    0.7    0.05     4  <0.1% <0.1%   0.2    0.2    0.01    17  0.1% 0.1% 
C01-14 mouth & pharynx   297  1.8% 2.7%   13.2    17.6    1.16    118  0.8% 1.2%   4.8    6.4    0.40    414  1.3% 2.0% 
C15 oesophagus   251  1.5% 2.3%   10.9    17.2    0.91    137  1.0% 1.4%   4.9    8.3    0.35    387  1.3% 1.9% 
C16 stomach   361  2.2% 3.3%   15.5    25.2    1.19    204  1.5% 2.1%   7.5    12.0    0.56    565  1.8% 2.7% 
C17 small intestine    52  0.3% 0.5%   2.3    3.4    0.19    36  0.3% 0.4%   1.4    2.0    0.11    88  0.3% 0.4% 
C18 colon   908  5.5% 8.2%   39.0    64.5    2.89    723  5.1% 7.5%   26.8    42.7    2.02    1,631  5.3% 7.8% 
C19 rectosigmoid junction   109  0.7% 1.0%   4.7    7.2    0.41    64  0.5% 0.7%   2.4    3.7    0.21    173  0.6% 0.8% 
C20 rectum   459  2.8% 4.1%   20.0    30.5    1.67    226  1.6% 2.3%   8.9    12.9    0.71    685  2.2% 3.3% 
C21 anus and anal canal    19  0.1% 0.2%   0.8    1.2    0.07    29  0.2% 0.3%   1.2    1.7    0.09    49  0.2% 0.2% 
C19-20 rectosigmoid junction and rectum   568  3.4% 5.1%   24.7    37.7    2.07    290  2.1% 3.0%   11.3    16.6    0.92    858  2.8% 4.1% 
C18-20 colorectum   1,476  8.9% 13.3%   63.8    102.2    4.91    1,013  7.2% 10.4%   38.1    59.3    2.92    2,489  8.1% 12.0% 
C18-21 colorectum and anus   1,495  9.0% 13.5%   64.6    103.4    4.97    1,043  7.4% 10.7%   39.3    60.9    3.01    2,538  8.3% 12.2% 
C22 liver and intrahepatic bile ducts   191  1.1% 1.7%   8.2    12.8    0.66    73  0.5% 0.8%   2.7    4.3    0.20    264  0.9% 1.3% 
C23 gallbladder    18  0.1% 0.2%   0.8    1.5    0.04    46  0.3% 0.5%   1.6    2.8    0.11    64  0.2% 0.3% 
C24 other and unspecified parts of biliary tract    63  0.4% 0.6%   2.7    4.5    0.20    60  0.4% 0.6%   2.1    3.6    0.14    123  0.4% 0.6% 
C25 pancreas   266  1.6% 2.4%   11.5    18.9    0.90    252  1.8% 2.6%   9.1    15.2    0.67    518  1.7% 2.5% 
C26 other and ill-defined digestive organs    15  0.1% 0.1%   0.6    1.1    0.04    18  0.1% 0.2%   0.6    1.1    0.03    33  0.1% 0.2% 
C30 nasal cavity and middle ear    7  <0.1% 0.1%   0.3    0.4    0.03     8  0.1% 0.1%   0.3    0.5    0.03    15  <0.1% 0.1% 
C31 accessory sinuses    7  <0.1% 0.1%   0.3    0.5    0.02     6  <0.1% 0.1%   0.3    0.3    0.03    13  <0.1% 0.1% 
C32 larynx   137  0.8% 1.2%   6.0    8.9    0.52    26  0.2% 0.3%   1.1    1.5    0.10    164  0.5% 0.8% 
C33 trachea    2  <0.1% <0.1%   0.1    0.1  <0.01     1  <0.1% <0.1%   -    -  <0.01     3  <0.1% <0.1% 
C34 bronchus and lung   1,301  7.8% 11.7%   56.1    91.7    4.39    1,077  7.7% 11.1%   41.2    64.6    3.43    2,378  7.8% 11.4% 
C33-34 bronchus, lung and trachea   1,303  7.8% 11.7%   56.2    91.8    4.39    1,078  7.7% 11.1%   41.2    64.7    3.43    2,381  7.8% 11.4% 
C37 thymus    3  <0.1% <0.1%   0.1    0.2    0.01     6  <0.1% 0.1%   0.2    0.3    0.02     9  <0.1% <0.1% 
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ICD10* cancer site (INCIDENCE)  MALES FEMALES  ALL 
N# Average annual number of cases 2012-2014 rounded to nearest integer 
ASR‡ Age-standardised rate/100,000- weighted by ESP~ 1976 and 2013 
Risk† Cumulative risk (%) to age 75 years    ESP~ European Standard Population 
 N# % all 
invasive 
% all 
invasive 
excl. NMSC 
ASR‡ 
ESP~ 
1976 
ASR‡ 
ESP 
2013 
Risk†  
75Y 
N# % all 
invasive 
% all 
invasive 
excl. NMSC 
ASR‡ 
ESP 
1976 
ASR‡ 
ESP 
2013 
Risk† 
 75Y 
 N# % all 
invasive 
% all 
invasive 
excl. NMSC 
C38 heart, mediastinum and pleura    8  <0.1% 0.1%   0.4    0.6    0.02     4  <0.1% <0.1%   0.2    0.2    0.01    12  <0.1% 0.1% 
C39 other and ill-defined sites in the respiratory system  0  - - - - -   0  - - - - -  0 - - 
C40 bone and articular cartilage of limbs    11  0.1% 0.1%   0.5    0.5    0.04    11  0.1% 0.1%   0.5    0.5    0.04    22  0.1% 0.1% 
C41 bone and articular cartilage of other and unspecified sites    9  0.1% 0.1%   0.4    0.5    0.03     7  <0.1% 0.1%   0.3    0.3    0.03    16  0.1% 0.1% 
C43 malignant melanoma of skin   467  2.8% 4.2%   20.2    29.8    1.53    501  3.6% 5.2%   20.0    26.6    1.56    968  3.2% 4.7% 
C44 other neoplasms of skin   5,517  33.2%    236.7    388.3   16.10    4,351  31.0%    163.1    253.9   11.70    9,868  32.2%  
C45 mesothelioma    39  0.2% 0.4%   1.7    2.8    0.15     5  <0.1% 0.1%   0.2    0.3    0.02    45  0.1% 0.2% 
C46 Kaposi sarcoma    9  0.1% 0.1%   0.4    0.4    0.03     1  <0.1% <0.1%   -    -    0.01    10  <0.1% <0.1% 
C47 peripheral nerves and autonomic nervous system    2  <0.1% <0.1%   0.1    0.1    0.01     1  <0.1% <0.1%   0.1    -    0.01     4  <0.1% <0.1% 
C48 retroperitoneum and peritoneum    6  <0.1% 0.1%   0.3    0.4    0.02    19  0.1% 0.2%   0.7    1.1    0.06    25  0.1% 0.1% 
C49 other connective and soft tissue    69  0.4% 0.6%   3.0    4.3    0.22    49  0.3% 0.5%   2.0    2.6    0.15    118  0.4% 0.6% 
C50 breast    29  0.2% 0.3%   1.2    2.0    0.11    2,919  20.8% 30.1%   121.6    156.4    9.52    2,947  9.6% 14.2% 
C51 vulva          51  0.4% 0.5%   2.0    2.9    0.16    51  0.2% 0.2% 
C52 vagina          14  0.1% 0.1%   0.5    0.8    0.03    14  <0.1% 0.1% 
C53 cervix uteri          277  2.0% 2.9%   11.5    12.7    0.89    277  0.9% 1.3% 
C54 corpus uteri          465  3.3% 4.8%   19.2    26.4    1.69    465  1.5% 2.2% 
C55 uterus, part unspecified          21  0.1% 0.2%   0.9    1.2    0.07    21  0.1% 0.1% 
C56 ovary          384  2.7% 4.0%   15.4    21.5    1.24    384  1.3% 1.8% 
C57 other and unspecified female genital organs          15  0.1% 0.2%   0.6    0.9    0.05    15  <0.1% 0.1% 
C58 placenta           2  <0.1% <0.1%   0.1    0.1  <0.01     2  <0.1% <0.1% 
C51-52,55,57,58 other gynaecological neoplasms          103  0.7% 1.1%   4.1    5.8    0.32    103  0.3% 0.5% 
C60 penis    35  0.2% 0.3%   1.5    2.4    0.10          35  0.1% 0.2% 
C61 prostate   3,364  20.2% 30.3%   148.4    214.5   13.34          3,364  11.0% 16.2% 
C62 testis   172  1.0% 1.5%   7.3    7.0    0.53          172  0.6% 0.8% 
C63 other and unspecified male genital organs    4  <0.1% <0.1%   0.2    0.3    0.01           4  <0.1% <0.1% 
C64 kidney, except renal pelvis   383  2.3% 3.5%   16.7    23.8    1.34    208  1.5% 2.1%   8.3    11.8    0.70    591  1.9% 2.8% 
C65 renal pelvis    15  0.1% 0.1%   0.6    1.1    0.04     9  0.1% 0.1%   0.3    0.5    0.03    24  0.1% 0.1% 
C66 ureter    16  0.1% 0.1%   0.7    1.2    0.06     8  0.1% 0.1%   0.3    0.5    0.02    24  0.1% 0.1% 
C67 bladder   304  1.8% 2.7%   13.0    23.0    0.91    134  1.0% 1.4%   4.7    8.1    0.30    438  1.4% 2.1% 
C68 other and unspecified urinary organs    3  <0.1% <0.1%   0.1    0.2    0.01     2  <0.1% <0.1%   0.1    0.1  <0.01     5  <0.1% <0.1% 
C69 eye and adnexa    31  0.2% 0.3%   1.4    1.8    0.11    24  0.2% 0.2%   0.9    1.2    0.08    55  0.2% 0.3% 
C70 meninges    3  <0.1% <0.1%   0.1    0.1    0.01     6  <0.1% 0.1%   0.2    0.3    0.01     8  <0.1% <0.1% 
C71 brain   200  1.2% 1.8%   8.7    11.5    0.73    156  1.1% 1.6%   6.3    8.1    0.51    356  1.2% 1.7% 
C72 spinal cord, cranial nerves and other parts of CNS    6  <0.1% 0.1%   0.3    0.3    0.02     8  0.1% 0.1%   0.3    0.3    0.02    14  <0.1% 0.1% 
C71-72 brain and spinal cord   207  1.2% 1.9%   9.0    11.8    0.75    164  1.2% 1.7%   6.7    8.4    0.53    371  1.2% 1.8% 
C73 thyroid gland    75  0.5% 0.7%   3.3    4.0    0.25    206  1.5% 2.1%   8.6    9.7    0.69    281  0.9% 1.4% 
C74 adrenal gland    8  <0.1% 0.1%   0.3    0.4    0.03     8  0.1% 0.1%   0.3    0.3    0.02    15  <0.1% 0.1% 
C75 other endocrine glands and related structures    7  <0.1% 0.1%   0.3    0.4    0.02     7  <0.1% 0.1%   0.3    0.4    0.02    14  <0.1% 0.1% 
C76 other and ill-defined sites    8  <0.1% 0.1%   0.4    0.6    0.03    17  0.1% 0.2%   0.6    1.0    0.04    25  0.1% 0.1% 
C77 secondary and unspecified lymph nodes    2  <0.1% <0.1%   0.1    0.2    0.01     2  <0.1% <0.1%   0.1    0.1    0.01     5  <0.1% <0.1% 
C80 neoplasm without specification of site   191  1.1% 1.7%   8.2    14.3    0.56    214  1.5% 2.2%   7.4    12.9    0.46    405  1.3% 1.9% 
C81 Hodgkin's disease    81  0.5% 0.7%   3.6    3.9    0.29    59  0.4% 0.6%   2.6    2.7    0.20    140  0.5% 0.7% 
C82 follicular [nodular] non-Hodgkin's lymphoma    90  0.5% 0.8%   4.0    5.2    0.35    103  0.7% 1.1%   4.3    5.7    0.39    193  0.6% 0.9% 
C83 diffuse non-Hodgkin's lymphoma   199  1.2% 1.8%   8.6    12.9    0.66    148  1.1% 1.5%   5.8    8.5    0.47    347  1.1% 1.7% 
C84 Peripheral and cutaneous T-cell lymphomas    39  0.2% 0.4%   1.7    2.3    0.14    25  0.2% 0.3%   1.0    1.4    0.10    64  0.2% 0.3% 
C85 other and unspecified types of non-Hodgkin lymphoma    92  0.6% 0.8%   3.9    6.3    0.31    75  0.5% 0.8%   2.8    4.4    0.23    167  0.5% 0.8% 
C82-85 all non-Hodgkin lymphoma   420  2.5% 3.8%   18.2    26.6    1.46    351  2.5% 3.6%   13.9    20.1    1.18    771  2.5% 3.7% 
C81-85 lymphoma (total)   500  3.0% 4.5%   21.8    30.5    1.74    410  2.9% 4.2%   16.5    22.8    1.38    911  3.0% 4.4% 
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ICD10* cancer site (INCIDENCE)  MALES FEMALES  ALL 
N# Average annual number of cases 2012-2014 rounded to nearest integer 
ASR‡ Age-standardised rate/100,000- weighted by ESP~ 1976 and 2013 
Risk† Cumulative risk (%) to age 75 years    ESP~ European Standard Population 
 N# % all 
invasive 
% all 
invasive 
excl. NMSC 
ASR‡ 
ESP~ 
1976 
ASR‡ 
ESP 
2013 
Risk†  
75Y 
N# % all 
invasive 
% all 
invasive 
excl. NMSC 
ASR‡ 
ESP 
1976 
ASR‡ 
ESP 
2013 
Risk† 
 75Y 
 N# % all 
invasive 
% all 
invasive 
excl. NMSC 
C88 immunoproliferative diseases    10  0.1% 0.1%   0.4    0.8    0.04     4  <0.1% <0.1%   0.1    0.2    0.01    14  <0.1% 0.1% 
C90 multiple myeloma    163  1.0% 1.5%   7.1    11.2    0.54    108  0.8% 1.1%   4.0    6.4    0.31    271  0.9% 1.3% 
C91 lymphoid leukaemia   165  1.0% 1.5%   7.2    10.3    0.57    101  0.7% 1.0%   4.1    5.2    0.32    266  0.9% 1.3% 
C92 myeloid leukaemia    97  0.6% 0.9%   4.2    6.4    0.28    73  0.5% 0.8%   2.9    4.0    0.24    171  0.6% 0.8% 
C93 monocytic leukaemia    2  <0.1% <0.1%   0.1    0.1    0.01     1  <0.1% <0.1%   -    -    0.01     2  <0.1% <0.1% 
C94 other leukaemias of specified cell type    6  <0.1% 0.1%   0.3    0.4    0.02     3  <0.1% <0.1%   0.1    0.1    0.01     9  <0.1% <0.1% 
C95 leukaemia of unspecified cell type    20  0.1% 0.2%   0.9    1.6    0.04    15  0.1% 0.2%   0.4    0.8    0.02    35  0.1% 0.2% 
C91-95 Leukaemia (total)   290  1.7% 2.6%   12.6    18.9    0.91    192  1.4% 2.0%   7.6    10.1    0.59    483  1.6% 2.3% 
C96 other and unspecified lymphoid and haematopoietic   175  1.1% 1.6%   7.6    12.3    0.55    122  0.9% 1.3%   4.6    7.0    0.37    297  1.0% 1.4% 
D00 carcinoma in situ of oral cavity, oesophagus and stomach    12      0.5    0.7    0.05     9      0.3    0.5    0.02    21    
D01 carcinoma in situ of other and unspecified digestive organs    18      0.8    1.1    0.07    15      0.6    0.8    0.05    33    
D02 carcinoma in situ of middle ear and respiratory system    13      0.5    0.8    0.04    10      0.4    0.5    0.04    22    
D03 melanoma in situ   269      11.6    17.3    0.92    301      12.1    16.7    1.01    570    
D04 carcinoma in situ of skin   758      32.6    53.3    2.54    1,067      38.8    65.3    2.96    1,825    
D05 carcinoma in situ of breast    1      0.1    0.1    <0.01    357      16.0    18.2    1.31    358    
D06 carcinoma in situ of cervix uteri          2,873      115.1    106.5    7.95    2,873    
D07 carcinoma in situ of other and unspecified genital organs    72      3.2    4.2    0.31    45      1.9    2.1    0.15    117    
D09 carcinoma in situ of other and unspecified sites    58      2.5    4.0    0.20    18      0.7    1.1    0.07    76    
D32 benign neoplasm of meninges    37      1.6    2.5    0.11    112      4.5    6.2    0.37    149    
D33 benign neoplasm of brain and other parts of CNS    20      0.9    1.0    0.08    19      0.8    1.0    0.06    39    
D32-33 benign neoplasm of meninges, brain & CNS    57      2.5    3.5    0.19    131      5.2    7.1    0.43    188    
D35 benign neoplasm of intracranial endocrine glands    47      2.1    2.6    0.15    40      1.7    1.9    0.14    87    
D37 neoplasm of uncertain/unknown behaviour of oral cavity and digestive organs    30      1.3    1.9    0.11    29      1.2    1.6    0.10    59    
D38 neoplasm of uncertain/unknown behaviour of middle ear and respiratory     5      0.2    0.3    0.02     4      0.2    0.3    0.01    10    
D39 neoplasm of uncertain/unknown behaviour of female genital organs          85      3.6    4.0    0.28    86    
D40 neoplasm of uncertain/unknown behaviour of male genital organs    2      0.1    0.1  <0.01           2    
D41 neoplasm of uncertain/unknown behaviour of urinary organs   194      8.4    13.1    0.65    69      2.7    4.0    0.22    263    
D42 neoplasm of uncertain/unknown behaviour of meninges    9      0.4    0.4    0.03    10      0.4    0.5    0.03    18    
D43 neoplasm of uncertain/unknown behaviour of brain and CNS    25      1.1    1.1    0.08    26      1.1    1.1    0.08    51    
D42-43 neoplasm of uncertain/unknown meninges, brain & CNS    34      1.5    1.5    0.11    36      1.5    1.6    0.11    70    
D44 neoplasm of uncertain/unknown behaviour of endocrine glands    12      0.5    0.6    0.04    13      0.6    0.6    0.05    25    
D47 other neoplasm of uncertain/unknown behaviour of haematopoietic tissue     69      3.0    5.1    0.20    55      2.2    3.3    0.18    125    
D48 neoplasm of uncertain/unknown behaviour of other and unspecified sites    58      2.5    3.9    0.17    46      2.0    2.1    0.15    104    
C71-72, D32-33, D42-43 invasive , benign, uncertain, brain & CNS   298      13.0    16.8    1.04    331      13.5    17.1    1.07    629    
*Incidence figures for C00-C96 and C96 presented in this report include polycythaemia vera, myelodysplastic syndromes and chronic myeloproliferative disease, considered malignant in ICDO3 but previously classed as uncertain behaviour (and 
previously coded under ICD10 codes D45-D47).  
** D00-D48 tumours in this report exclude polycythaemia vera, myelodysplastic syndromes and chronic myeloproliferative disease (see note above). 
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APPENDIX II: SUMMARY TABLE - CANCER DEATHS: ANNUAL AVERAGE 2011-2013 
 
ICD10 cancer site (MORTALITY‡) MALES FEMALES ALL 
N#: Average annual number of deaths 2011-2012 rounded to nearest integer 
ASR‡: Age-standardised rate/100,000 - weighted by European Standard Population (ESP~) of 1976 
Risk†: Cumulative risk of death (%) due to listed cancer up to age 75 years 
N# % of all 
cancer 
deaths 
ASR‡ 
ESP~ 
1976 
Risk† 
75Y 
% 
N# % of all 
cancer 
deaths 
ASR‡ 
ESP 
1976 
Risk† 
75Y 
% 
N# % of all 
cancer 
deaths 
C00-96 all cancers   4,590  100.0%  203.56    12.7      4,065  100.0%  149.20    10.1   8,655  100.0% 
C00-96/C33-34 all cancers but lung & trachea   3,511  76.5%  155.82      9.5      3,317  81.6%  121.05      8.1   6,828  78.9% 
C00-14 mouth & pharynx     117  2.5%     5.27      0.4         48  1.2%     1.82      0.1     165  1.9% 
C00-15,C32 mouth, pharynx, larynx and oesophagus     411  9.0%   18.44      1.5        185  4.6%     6.66      0.5     597  6.9% 
C11 nasopharynx       7  0.1%     0.31  <0.1         3  0.1%     0.13  <0.1     10  0.1% 
C15 oesophagus     240  5.2%   10.72      0.8        129  3.2%     4.52      0.3     369  4.3% 
C16 stomach     193  4.2%     8.59      0.6        119  2.9%     4.17      0.3     313  3.6% 
C18 colon     290  6.3%   12.89      0.8        247  6.1%     8.30      0.5     537  6.2% 
C19-21 rectum and anus     305  6.6%   13.49      0.9        177  4.3%     6.45      0.4     481  5.6% 
C18-21 colon, rectum and anus     594  12.9%   26.37      1.7        424  10.4%   14.75      0.9   1,018  11.8% 
C17-21 intestine     605  13.2%   26.84      1.7        436  10.7%   15.18      1.0   1,041  12.0% 
C22 liver     157  3.4%     6.95      0.5        111  2.7%     3.87      0.2     268  3.1% 
C22-24 liver and biliary passages     176  3.8%     7.78      0.6        142  3.5%     4.96      0.3     318  3.7% 
C23-24 gallbladder      19  0.4%     0.84  <0.1        31  0.8%     1.09      0.1      50  0.6% 
C25 pancreas     246  5.4%   10.90      0.8        237  5.8%     8.48      0.6     483  5.6% 
C32 larynx      55  1.2%     2.45      0.2          8  0.2%     0.33  <0.1     63  0.7% 
C33-34 lung   1,079  23.5%   47.74      3.5        749  18.4%   28.15      2.1   1,827  21.1% 
C43 melanoma of skin      89  1.9%     3.96      0.3         70  1.7%     2.56      0.2     159  1.8% 
C45 mesothelioma      33  0.7%     1.43      0.1          4  0.1%     0.16  <0.1     37  0.4% 
C50 breast           694  17.1%   26.55      2.0     694  8.0% 
C53 cervix uteri            89  2.2%     3.77      0.3      89  1.0% 
C53-55 uterus           195  4.8%     7.66      0.6     195  2.3% 
C54 corpus uteri            82  2.0%     3.01      0.2      82  0.9% 
C56 ovary           272  6.7%   10.58      0.8     272  3.1% 
C61 prostate     527  11.5%   23.39      1.0         527  6.1% 
C62 testis       7  0.2%     0.30  <0.1          7  0.1% 
C64 kidney     144  3.1%     6.41      0.5         70  1.7%     2.58      0.2     214  2.5% 
C67 bladder     141  3.1%     6.24      0.3         72  1.8%     2.24      0.1     213  2.5% 
C70-72 brain & CNS     157  3.4%     6.96      0.6        108  2.7%     4.40      0.4     265  3.1% 
C73 thyroid      10  0.2%     0.45  <0.1        18  0.5%     0.66  <0.1     29  0.3% 
C81 Hodgkin lymphoma      12  0.3%     0.53  <0.1        12  0.3%     0.47  <0.1     24  0.3% 
C82-85 non-Hodgkin lymphoma     134  2.9%     5.94      0.3        130  3.2%     4.66      0.3     264  3.0% 
C90 multiple myeloma      94  2.0%     4.15      0.3         79  2.0%     2.65      0.2     173  2.0% 
C91-95 leukaemia     161  3.5%     7.05      0.4        104  2.6%     3.65      0.2     264  3.1% 
‡Data abstracted from the WHO mortality database [3] 
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APPENDIX III: COMPARISON OF INCIDENCE RATES FOR 2012-2014 USING 1976 AND 2013 EUROPEAN STANDARD POPULATION WEIGHTS 
 
MALES FEMALES 
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Comparison of incidence rates standardised using the ‘old’ (1976) and ‘new’ (2013) European standard populations 
The age-standardised (ASR) rate for any specified disease is the annual rate of newly diagnosed cases (or deaths) in a given 
population (and year), expressed per 100,000 persons, weighted by the age-structure of a defined ‘standard’ population in 
order to allow meaningful comparisons between different European countries or over time.  
By convention for European cancer registries, age-standardised rates for incidence and mortality are typically weighted by 
the European standard population (ESP) as defined in 1976 [4]. However, in this report (Appendix I and III) the NCR has also 
presented rates weighted by the 2013 ESP proposed by EUROSTAT to more accurately reflect the demographic age shift in 
the European population since 1976 [20]. The 2013 ESP is a better reflection of the current population structure than the ESP 
of 1976, and gives older ages a greater weight than the 1976 ESP (see Methods section). 
In general, incidence rates for cancer sites during 2012-2014 tended to be higher when calculated using the more recent age 
weights (ESP 2013). This is more apparent for cancer sites with older median age of incidence, e.g. bladder cancer (74 years), 
which tended to have a much greater relative difference in rates between the ESP 1976 and ESP 2013 calculations than 
cancers with a lower median age at diagnosis, e.g. Hodgkin lymphoma (38 years).  
The NCR will continue to publish incidence rates using the 1976 standard population but with rates also provided based on 
the 2013 standard, both in published reports and (when the necessary programming has been completed) on the NCR 
website. For this report we were not able to provide mortality rates using the 2013 ESP age weights because the WHO 
mortality statistics were only available in the conventional 18 category age bands. 
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APPENDIX IV: PREVALENCE OF INVASIVE CANCER (EXCLUDING NMSC) AT THE END OF 2014 – NUMBERS OF CANCER SURVIVORS BY DIAGNOSIS 
PERIOD 
 
 Diagnosis period (years since diagnosis) and % of cancer survivors who were diagnosed in each period  
Cancer site & ICD10 code  1994-2014   2013-2014   2010-2012   2005-2009   2000-2004   1994-1999  
 (0-21]  % (0-<2]  % (2-<5] % (5-<10]  % (10-<15]  % (>15]  % 
C00-43, C45-96 all invasive               139,526  100.0%                 29,285  21%                 34,044  24%                 38,531  28%                 23,004  16%                 14,662  11% 
C50 breast                 31,655  100.0%                  5,639  18%                  7,266  23%                  9,063  29%                  5,872  19%                  3,815  12% 
C61 prostate                 30,642  100.0%                  6,380  21%                  8,906  29%                  9,614  31%                  4,596  15%                  1,146  4% 
C18-20 colorectum                 17,136  100.0%                  3,862  23%                  4,199  25%                  4,524  26%                  2,618  15%                  1,933  11% 
C43 melanoma of skin                  9,254  100.0%                  1,922  21%                  2,211  24%                  2,390  26%                  1,560  17%                  1,171  13% 
C82-85 non-Hodgkin                   5,932  100.0%                  1,251  21%                  1,432  24%                  1,621  27%                  1,001  17%                     627  11% 
C33-34 lung                  4,791  100.0%                  2,136  45%                  1,183  25%                     823  17%                     379  8%                     270  6% 
C54 corpus uteri                  4,183  100.0%                     831  20%                     976  23%                  1,100  26%                     722  17%                     554  13% 
C91-95 leukaemia                  4,052  100.0%                     680  17%                     946  23%                  1,215  30%                     740  18%                     471  12% 
C64 kidney                  3,851  100.0%                     898  23%                  1,048  27%                  1,021  27%                     534  14%                     350  9% 
C67 bladder                  3,659  100.0%                     629  17%                     656  18%                     931  25%                     776  21%                     667  18% 
C53 cervix uteri                  3,128  100.0%                     480  15%                     712  23%                     890  28%                     542  17%                     504  16% 
C62 testis                  2,749  100.0%                     329  12%                     512  19%                     833  30%                     597  22%                     478  17% 
C01-14 mouth & pharynx                  2,416  100.0%                     646  27%                     642  27%                     610  25%                     303  13%                     215  9% 
C73 thyroid gland                  2,279  100.0%                     549  24%                     654  29%                     600  26%                     282  12%                     194  9% 
C56 ovary                  2,183  100.0%                     527  24%                     489  22%                     495  23%                     352  16%                     320  15% 
C16 stomach                  1,855  100.0%                     614  33%                     461  25%                     388  21%                     217  12%                     175  9% 
C81 Hodgkin lymphoma                  1,729  100.0%                     270  16%                     354  20%                     448  26%                     357  21%                     300  17% 
C71-72 brain and spinal cord                  1,382  100.0%                     395  29%                     292  21%                     287  21%                     207  15%                     201  15% 
C90 multiple myeloma                   1,358  100.0%                     449  33%                     404  30%                     332  24%                     110  8%                      63  5% 
C32 larynx                  1,197  100.0%                     270  23%                     304  25%                     314  26%                     184  15%                     125  10% 
C15 oesophagus                  1,038  100.0%                     412  40%                     232  22%                     227  22%                     105  10%                      62  6% 
C51-52,55,57,58 gynaecological                     752  100.0%                     156  21%                     179  24%                     205  27%                     120  16%                      92  12% 
C25 pancreas                     659  100.0%                     352  53%                     129  20%                      92  14%                      47  7%                      39  6% 
C22 liver                      498  100.0%                     232  47%                     136  27%                      76  15%                      40  8%                      14  3% 
C17 small intestine                     432  100.0%                     123  28%                     120  28%                      97  22%                      58  13%                      34  8% 
C40 bone                     234  100.0%                      36  15%                      46  20%                      48  21%                      53  23%                      51  22% 
C45 mesothelioma                      59  100.0%                      37  63%                      12  20%                        3  5%                        2  3%                        5  8% 
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APPENDIX V: PREVALENCE OF INVASIVE CANCER (EXCLUDING NMSC) – PERCENTAGE OF PATIENTS DIAGNOSED IN EACH PERIOD WHO WERE STILL 
ALIVE AT THE END OF 2014  
 
 Diagnosis period (years since diagnosis) and % of incident cases in each period still alive at 31/12/2014  
Cancer site & ICD10 code 1994-2014 2013-2014 2010-2012 2005-2009 2000-2004 1994-1999 
 (0-21] alive 
% 
(0-<2]  alive 
% 
(2-<5] alive 
% 
(5-<10]  alive 
% 
(10-<15]  alive 
% 
(>15]  alive 
% 
C00-43, C45-96 all invasive cancers      139,526           43         29,285            77         34,044           61         38,531           47         23,004           32         14,662           20  
C62 testis         2,749           94            329            99            512           96            833           96            597           93            478           85  
C81 Hodgkin lymphoma         1,729           77            270            92            354           86            448           79            357           76            300           61  
C73 thyroid          2,279           79            549            92            654           89            600           82            282           64            194           52  
C43 melanoma of skin         9,254           71          1,922            95          2,211           83          2,390           69          1,560           61          1,171           50  
C53 cervix uteri         3,128           63            480            89            712           76            890           64            542           54            504           47  
C54 corpus uteri         4,183           64            831            89            976           77          1,100           65            722           54            554           43  
C40 bone            234           58              36            88              46           66              48           60              53           56              51           43  
C50 breast        31,655           66          5,639            95          7,266           85          9,063           72          5,872           55          3,815           38  
C82-C85 non-Hodgkin lymphoma         5,932           50          1,251            80          1,432           65          1,621           54          1,001           39            627           26  
C67 bladder         3,659           38            629            71            656           50            931           40            776           33            667           24  
C64 kidney         3,851           46            898            77          1,048           63          1,021           46            534           30            350           23  
C51-52,55,57,58 gynaecological           752           43            156            78            179           57            205           44            120           34              92           23  
C91-95 Leukaemia          4,052           42            680            75            946           59          1,215           48            740           32            471           21  
C32 larynx         1,197           42            270            84            304           61            314           44            184           29            125           19  
C18-20 colorectum        17,136           40          3,862            80          4,199           58          4,524           41          2,618           27          1,933           18  
C56 ovary         2,183           31            527            69            489           44            495           29            352           21            320           18  
C17 small intestine           432           38            123            68            120           55              97           35              58           24              34           16  
C61 prostate        30,642           63          6,380            96          8,906           86          9,614           70          4,596           43          1,146           15  
C01-14 mouth & pharynx         2,416           39            646            78            642           56            610           40            303           25            215           15  
C71-72 brain and spinal cord         1,382           22            395            53            292           28            287           18            207           14            201           13  
C16 stomach         1,855           18            614            54            461           28            388           16            217             9            175             6  
C90 multiple myelomas         1,358           29            449            81            404           54            332           27            110           10              63             6  
C45 mesothelioma             59           10              37            45              12           10               3             2               2             2               5             5  
C15 oesophagus         1,038           15            412            53            232           21            227           13            105             6              62             4  
C22 liver            498           16            232            43            136           21              76             9              40             7              14             4  
C33-34 lung          4,791           12          2,136            45          1,183           17            823             8            379             4            270             3  
C25 pancreas           659             8            352            33            129             9              92             4              47             3              39             2  
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APPENDIX VI: 5-YEAR AND 10-YEAR NET SURVIVAL – OVERALL (AGE-STANDARDISED) AND BY AGE-GROUP 
 
Cancer  5-yr net survival (with 95% CI2) 10-yr net survival (with 95% CI) 
(ICD10 code) Sex All ages1 15-44 45-54 55-64 65-74 75-99 All ages 15-44 45-54 55-64 65-74 75-99 
All cancers ex NMSC3 All 61.1% 82.8% 75.6% 69.9% 62.6% 41.6% 56.6% 77.7% 70.2% 64.5% 57.2% 39.0% 
(C00-C43,45-97)  60.7-61.5% 81.9-83.5% 74.7-76.3% 69.2-70.5% 61.8-63.2% 40.6-42.5% 55.9-57.1% 76.6-78.6% 69.1-71.0% 63.6-65.2% 56.2-58.1% 37.1-40.7% 
All cancers ex NMSC Male 61.7% 79.0% 69.2% 69.7% 66.2% 43.7% 57.8% 75.5% 64.3% 64.8% 61.8% 41.1% 
(C00-C43,45-97)  61.1-62.2% 77.4-80.4% 67.8-70.5% 68.7-70.5% 65.2-67.0% 42.3-44.9% 56.8-58.7% 73.8-77.0% 62.6-65.8% 63.7-65.9% 60.5-63.0% 38.3-43.8% 
All ex NMSC Female 59.5% 85.0% 79.9% 70.2% 56.5% 39.3% 54.2% 78.8% 74.2% 64.1% 49.7% 36.6% 
(C00-C43,45-97)  58.9-60.0% 83.9-85.9% 78.8-80.8% 69.2-71.1% 55.3-57.6% 38.0-40.6% 53.3-54.9% 77.6-80.0% 72.9-75.3% 62.9-65.2% 48.3-51.0% 34.3-38.7% 
Head & neck4 All 49.5% 81.6% 60.2% 56.7% 47.7% 33.4% 39.8% 77.2% 51.6% 46.5% 38.6% 21.7% 
(C01-06,09-13)  46.0-52.9% 73.2-87.5% 54.1-65.7% 51.5-61.4% 41.5-53.6% 24.4-42.6% 33.4-46.1% 67.8-84.1% 44.9-57.8% 40.4-52.3% 31.4-45.6% 6.2-43.1% 
Oesophagus All 21.5% 31.9% 32.1% 26.4% 23.7% 8.4% 18.3% 23.7% 26.2% 23.0% 19.9% 8.4% 
(C15)  19.2-23.7% 19.2-45.1% 24.6-39.7% 21.8-31.2% 19.6-27.9% 5.9-11.5% 15.8-20.7% 12.3-37.1% 18.9-33.9% 18.2-28.0% 14.8-25.4% 5.7-11.7% 
Stomach All 27.3% 37.1% 32.5% 29.9% 31.3% 16.8% 24.5% 35.8% 28.2% 28.6% 28.4% 13.0% 
(C16)  25.2-29.3% 28.7-45.4% 26.0-39.1% 25.5-34.3% 27.5-35.1% 13.5-20.2% 21.9-27.0% 27.3-44.3% 21.7-34.9% 24.0-33.2% 23.7-33.2% 8.2-18.8% 
Colon & rectum All 62.6% 74.2% 69.0% 66.4% 64.7% 52.0% 57.0% 69.6% 60.8% 58.9% 58.9% 49.1% 
(C18-21)  61.4-63.6% 69.8-78.0% 66.0-71.7% 64.2-68.3% 62.6-66.6% 49.4-54.3% 55.1-58.9% 64.7-73.8% 57.4-63.8% 56.4-61.2% 56.2-61.3% 43.5-54.4% 
Liver All 16.4% 34.3% 19.6% 21.4% 14.4% 8.6% 10.6% 25.8% 15.0% 12.8% 11.8% 2.1% 
(C22)  13.6-19.0% 21.8-47.1% 11.9-28.6% 15.8-27.5% 9.8-19.8% 4.9-13.6% 7.7-13.5% 10.7-43.9% 8.0-24.0% 7.7-19.3% 6.9-18.1% 0.1-10.1% 
Pancreas All 9.7% 27.3% 14.2% 11.1% 8.4% 4.0% 7.5% 27.3% 10.6% 7.0% 6.6% 2.7% 
(C25)  8.1-11.3% 14.8-41.2% 9.4-19.9% 8.1-14.5% 6.2-11.0% 2.5-5.8% 5.8-9.2% 14.8-41.2% 6.2-16.3% 3.8-11.4% 4.3-9.6% 1.2-5.1% 
Lung & trachea All 17.9% 51.8% 19.7% 19.6% 16.1% 9.6% 15.1% 47.3% 17.2% 16.0% 11.6% 9.4% 
(C33-34)  16.9-18.8% 44.0-59.0% 16.7-22.8% 17.7-21.3% 14.6-17.5% 8.2-11.0% 14.0-16.2% 38.9-55.2% 14.2-20.2% 14.1-17.8% 10.0-13.2% 7.5-11.5% 
Melanoma skin All 88.7% 92.3% 90.9% 89.4% 88.3% 78.6% 85.7% 89.6% 86.1% 85.0% 87.1% 76.7% 
(C43)  87.3-90.1% 90.2-93.9% 88.0-93.1% 86.3-91.8% 84.5-91.1% 71.3-84.1% 83.3-88.1% 87.1-91.5% 82.2-89.2% 80.8-88.3% 80.7-91.4% 60.7-86.8% 
Breast Female 82.9% 87.9% 91.6% 90.9% 84.2% 70.5% 75.1% 79.0% 86.1% 84.2% 75.3% 62.4% 
(C50)  81.7-84.1% 86.2-89.3% 90.5-92.5% 89.7-91.9% 82.2-86.0% 66.8-73.8% 73.1-77.1% 76.9-80.9% 84.6-87.3% 82.5-85.7% 72.3-77.9% 55.7-68.2% 
Cervix uteri Female 62.3% 85.3% 74.2% 60.4% 45.4% 28.9% 55.2% 80.0% 66.8% 50.0% 37.9% 24.3% 
(C53)  59.1-65.4% 82.5-87.6% 68.6-78.8% 53.5-66.5% 34.9-55.3% 17.9-40.6% 51.2-59.1% 76.5-82.9% 60.5-72.2% 42.0-57.3% 26.6-49.0% 9.7-42.3% 
Corpus uteri Female 76.2% 84.9% 91.4% 84.4% 79.1% 58.3% 70.9% 83.5% 87.1% 81.4% 77.1% 46.7% 
(C54)  73.2-79.0% 74.1-91.4% 87.1-94.2% 80.9-87.2% 74.4-83.0% 49.5-66.1% 66.3-75.5% 72.4-90.4% 81.5-91.0% 77.1-85.0% 70.5-82.3% 32.1-59.9% 
Ovary & related Female 34.4% 69.0% 56.7% 40.0% 29.3% 17.4% 28.9% 59.5% 48.8% 32.5% 22.8% 16.7% 
(C56,C57.0-C57.7)  31.8-36.8% 61.4-75.2% 50.3-62.5% 35.0-44.7% 24.5-34.2% 12.8-22.5% 26.0-31.8% 51.5-66.5% 42.3-54.8% 27.6-37.4% 17.9-27.9% 10.4-24.2% 
Testis5 Male 96.3% 98.1% 96.8% 84.5% - - 95.5% 97.8% 96.8% 80.7% - - 
(C62)  93.9-98.5% 96.6-98.9% 89.6-99.0% 56.9-95.0%   92.9-98.1% 96.0-98.7% 89.6-99.0% 52.6-93.0%   
Kidney & related All 60.3% 79.0% 75.4% 66.5% 62.3% 42.5% 49.5% 71.7% 71.6% 58.6% 50.6% 26.8% 
(C64-66,68)  57.7-62.7% 72.7-83.9% 70.3-79.7% 62.3-70.3% 57.6-66.5% 36.3-48.4% 46.1-52.9% 64.2-77.8% 65.6-76.6% 53.5-63.3% 44.4-56.4% 18.4-35.8% 
Brain (malignant) All 25.2% 59.2% 26.5% 10.1% 6.6% 4.8% 19.9% 45.1% 21.8% 8.5% 5.4% 4.8% 
(C71)  23.0-27.3% 53.4-64.4% 20.2-33.0% 6.9-14.0% 3.9-10.1% 2.2-8.9% 17.6-22.1% 39.0-50.9% 15.9-28.2% 5.4-12.4% 2.7-9.5% 2.1-9.1% 
Non-Hodgkin lymphoma All 67.2% 86.9% 85.4% 77.5% 69.9% 44.0% 61.0% 85.0% 78.8% 70.0% 59.5% 42.4% 
(C82-85)  65.1-69.2% 83.0-89.9% 81.6-88.4% 73.8-80.7% 65.9-73.5% 38.7-49.1% 57.6-64.4% 80.7-88.3% 74.0-82.7% 65.3-74.0% 54.0-64.5% 32.6-51.7% 
Leukaemia All 61.6% 71.4% 80.6% 75.0% 59.8% 42.5% 52.3% 66.4% 72.9% 65.8% 45.0% 37.0% 
(C91-95)  59.1-64.0% 65.5-76.4% 74.7-85.3% 70.1-79.2% 54.8-64.3% 36.8-47.9% 48.4-56.1% 60.2-71.8% 66.0-78.5% 59.9-70.9% 39.2-50.4% 26.2-47.6% 
  All ages 15-54 55-64 65-74 75-84 85-99 All ages 15-54 55-64 65-74 75-84 85-99 
Prostate Male 92.1% 97.8% 97.5% 98.1% 84.1% 55.4% 88.7% 97.6% 96.0% 96.7% 75.6% 44.5% 
(C61)  91.1-93.0% 96.2-98.7% 96.5-98.1% 96.7-98.9% 81.0-86.7% 45.3-64.2% 86.8-90.5% 94.7-98.6% 94.2-97.1% 93.9-98.2% 69.7-80.4% 21.5-59.9% 
1  5-year and 10-year net survival (age-standardised for ages 15-99 combined and age-specific survival) for invasive cancers in Ireland: 2010-2014 (cases diagnosed or followed-up during this period) survival for all ages 15-99 is standardised to the 
standard populations recommended by Corazziari et al. (2004). The age-groups used differ for prostate cancer, giving greater weighting to older patients, while greater weighting is given to younger patients for melanoma [17] 
2 95% confidence interval.    3 Non-melanoma skin cancer. 
4 Head & neck cancer definition here is the one used by EUROCARE, which excludes lip, salivary glands and unspecified subsites. 
5 Only ages 15-64 are included, by international convention, in age-standardised estimates of testicular cancer survival. 
 
